Prophylactic use of Rh D immunoglobulin in pregnancy care

2021
Acknowledgements

This guideline was developed by a multidisciplinary Expert Reference Group (ERG) with expertise from a range of clinical settings. Membership of the ERG included representation of the following clinical colleges and organisations.

Australian and New Zealand Society of Blood Transfusion

Australian College of Midwives

Australian Red Cross Lifeblood

Royal Australian College of General Practitioners

Royal Australasian College of Physicians

Royal Australian and New Zealand College of Obstetricians and Gynaecologists

Royal College of Pathologists of Australasia

The National Blood Authority gratefully acknowledges the expertise and clinical input provided by the ERG. Membership of the ERG is provided at Appendix D.

Endorsement of this guideline from clinical colleges and societies can be found at www.blood.gov.au.

The development of the Guideline for the prophylactic use of Rh D immunoglobulin in pregnancy care was a joint project between the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) and the National Blood Authority, Australia (NBA). The NBA provided project management oversight and funded all goods and services associated with the development of this guideline. The development of the clinical guidance was not influenced by the views or interests of the funding body.
Contents

Copyright and disclaimer ........................................................................................................... i
Acknowledgements ................................................................................................................... ii

Summary of clinical guidance .................................................................................................. 1
  Care pathway for the prophylactic use of Rh D immunoglobulin in pregnancy care ............ 1
  Summary of guidance on the use and timing of pathology testing .................................... 2
  Summary of guidance on the use and timing of Rh D immunoglobulin for routine
  immunoprophylaxis .............................................................................................................. 3
  Summary of guidance on the use and timing of Rh D immunoglobulin for sensitising event
  immunoprophylaxis .............................................................................................................. 4
  Products available under the National Blood Arrangements .............................................. 5
  Summary of recommendations and expert opinion points ................................................. 6

1 Introduction ........................................................................................................................... 10
  1.1 Background ..................................................................................................................... 10
  1.2 The national prophylaxis program .................................................................................. 11
  1.3 Clinical need for this guideline ....................................................................................... 11
  1.4 Intent of the guideline ..................................................................................................... 12
  1.5 Structure of the guideline ............................................................................................... 12
  1.6 Related material ............................................................................................................. 13

2 Methodology .......................................................................................................................... 14
  2.1 Question development ................................................................................................... 14
  2.2 Systematic review process ............................................................................................. 14
  2.3 Literature search ............................................................................................................ 15
  2.4 Formulating recommendations ...................................................................................... 15
  2.5 Study selection ................................................................................................................ 17
  2.6 Strength and limitations of the evidence ........................................................................ 17

3 Clinical guidance ..................................................................................................................... 19
  3.1 Routine antenatal Rh D immunoprophylaxis ................................................................. 19
  3.2 Universal sensitising event immunoprophylaxis in the first 12 weeks of pregnancy ...... 29
  3.3 Targeted routine antenatal or sensitising event immunoprophylaxis ............................. 36
  3.4 Risk of failure of Rh D immunoprophylaxis due to high BMI ......................................... 49
  3.5 Guidance based on the 2003 Guidelines on the prophylactic use of Rh D immunoglobulin
      (anti-D) in obstetrics ........................................................................................................ 54

4 Cost considerations ................................................................................................................ 57

5 Supply considerations ............................................................................................................. 59
  5.1 Products currently available under the national blood arrangements ......................... 59
  5.2 Supply trends .................................................................................................................... 59
6 Safety of Rh D immunoglobulin .................................................................................. 61
  6.1 The effect of circulating prophylactically administered Rh D immunoglobulin in the fetal
  circulation ....................................................................................................................... 61
  6.2 The risk of transmission of infectious organisms by administering Rh D immunoglobulin .... 61
  6.3 Other risks and benefits .......................................................................................... 62
7 Challenges ................................................................................................................... 63
  7.1 Donors ..................................................................................................................... 63
  7.2 Care pathways ......................................................................................................... 63
  7.3 Measurement of product usage against clinical guidance ........................................ 64
  7.4 Consent and the choice to decline Rh D immunoglobulin ....................................... 65
8 Monitoring the use of Rh D immunoglobulin .................................................................. 66
  8.1 Documenting the use of Rh D immunoglobulin ..................................................... 66
  8.2 Adverse event reporting and monitoring .............................................................. 66
  8.3 Audits ...................................................................................................................... 66
9 Implementing, evaluating and maintaining the guideline ..................................................... 68
  9.1 Communication and education ............................................................................... 68
  9.2 Review of these guidelines .................................................................................... 68
  9.3 Feedback .................................................................................................................. 68
References ....................................................................................................................... 69
Appendix A1 Abbreviations and acronyms ..................................................................... 78
Appendix A2 Terminology ............................................................................................... 79
Appendix B Evidence gaps for potential research priorities ............................................. 81
Appendix C Dosing of Rh D immunoglobulin following fetomaternal haemorrhage quantitation .... 82
Appendix D Governance .................................................................................................. 83
  D1 Governance framework ......................................................................................... 83
  D2 Membership ......................................................................................................... 84
Appendix E Process report ............................................................................................... 85
  E1 Methodology ......................................................................................................... 85
  E2 Consensus process .............................................................................................. 85
  E3 Conflict of interest .............................................................................................. 86
  E4 Public consultation .............................................................................................. 87
  E5 Appraisal of the guideline ................................................................................... 87
Summary of clinical guidance

Care pathway for the prophylactic use of Rh D immunoglobulin in pregnancy care

Woman's blood group and antibody screen in pregnancy confirms Rh D negative

Antibody screen positive for anti-D

Clinical history of:
- Previous pregnancy
- Transfusion
- IV drug use/needle sharing
- Recent Rh D Ig administration

Discuss with your laboratory to determine whether likely to be passive or preformed antibody

Like ly preformed anti-D

No

Rh D Ig not required. Seek specialist obstetric advice and manage as Rh D sensitised. Consider NIFT for fetal RHD status.

Yes

Rh D Ig not required. Seek specialist obstetric advice and manage as Rh D sensitised. Consider NIFT for fetal RHD status.

Antibody screen negative for anti-D

From 11+ weeks of pregnancy

Determine fetal RHD status via non-invasive prenatal testing of maternal blood sample from 11+ weeks

Fetus predicted to be RHD positive, or:
- Test inconclusive, or
- Results unavailable or uncertain

No

All fetuses predicted to be RHD negative - no antenatal immunoprophylaxis required

Yes

Consider clinical history and discuss with your laboratory whether likely to be passive or preformed antibody

At 28 weeks of pregnancy

Retest antibody screen and administer first dose of Rh D Ig 625 IU. Dose can be given before results are available.

Negative

At 34 weeks of pregnancy

Administer second dose of Rh D Ig 625 IU

Likely preformed anti-D

No

Rh D Ig not required. Seek specialist obstetric advice and manage as Rh D sensitised.

Yes

Rh D Ig not required. Seek specialist obstetric advice and manage as Rh D sensitised.

Additional Rh D Ig for sensitising events in singleton and multiple pregnancies

**First 12 weeks of pregnancy**

Administer Rh D Ig 250 IU as soon as practical. If delayed beyond 72 hours the dose should be given up to 10 days from the sensitising event, but may have lower efficacy.

**Between 13 and 20 weeks of pregnancy**

Administer Rh D Ig 625 IU as soon as practical, unless testing has confirmed that they are not carrying an Rh D positive fetus. If delayed beyond 72 hours the dose should be given up to 10 days from the sensitising event, but may have lower efficacy.

**After 20 weeks of pregnancy**

Maternal blood sample for volume of FMH. If large FMH, 6 ml of fetal red cells (12 ml of whole blood) confirmed, follow laboratory or medical advice regarding additional Rh D Ig to be given.

One or more neonates Rh D positive

Maternal blood sample for volume of FMH

Administer Rh D Ig 625 IU to woman as soon as practical (without waiting for result of test for FMH). If delayed beyond 72 hours the dose should be given up to 10 days

No

If large FMH, 6 ml of fetal red cells (12 ml of whole blood) confirmed, follow laboratory or medical advice regarding additional Rh D Ig to be given.

Fetal blood or neonatal testing to determine Rh type

After birth

Administer second dose of Rh D Ig 625 IU

R HD Ig required

Rh D Ig not required

Policy relating to universal access to NIFT for fetal RHD is outside the scope of this guideline. The pathway is designed to be adapted to meet the needs and operations of individual organisations.

Adapted from NSW Health (2015)

FMH, fetomaternal haemorrhage; Ig, immunoglobulin; IU, international units; IV, intravenous.

anti-D - refers to circulating antibodies; RHD - refers to genotype; Rh D positive/negative - refers to blood type.
## Summary of guidance on the use and timing of pathology testing

<table>
<thead>
<tr>
<th>Test</th>
<th>Timing</th>
<th>Target group</th>
<th>Relevant section of Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABO/Rh D type and antibody screen</td>
<td>First visit (at approximately 10 weeks)</td>
<td>All pregnant women</td>
<td>3.1.1</td>
</tr>
<tr>
<td>NIPT for fetal RHD</td>
<td>From 11(^{o}) weeks of pregnancy</td>
<td>All Rh D negative pregnant women</td>
<td>3.3.1</td>
</tr>
<tr>
<td>Magnitude of FMH(^a)</td>
<td>• After 20 weeks of pregnancy</td>
<td>Rh D negative women following birth or a sensitising event during pregnancy (after 20 weeks)</td>
<td>3.5.1</td>
</tr>
<tr>
<td></td>
<td>• At delivery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rh D type and antibody screen (Retest)</td>
<td>28 weeks (prior to administration of Rh D immunoglobulin)</td>
<td>Rh D negative pregnant women (unless NIPT for fetal RHD has predicted that they are not carrying an Rh D positive fetus)</td>
<td>3.1.1</td>
</tr>
<tr>
<td>Cord blood or neonatal testing for Rh D type and direct antiglobulin test</td>
<td>At delivery</td>
<td>All babies of Rh D negative women</td>
<td>3.3.1</td>
</tr>
<tr>
<td>Follow up testing for large FMH(^b)</td>
<td>48 hours post IV Rh D immunoglobulin administration (or 72 hours post IM Rh D immunoglobulin administration)</td>
<td>Rh D negative women following FMH ≥ 6 mL of fetal red cells (equivalent to 12 mL of whole fetal blood)</td>
<td>3.5.1</td>
</tr>
</tbody>
</table>

FMH: fetomaternal haemorrhage; IM: intramuscular; IV: intravenous; NIPT: non-invasive prenatal testing

anti-D - refers to circulating antibodies; RHD - refers to genotype; Rh D immunoglobulin - refers to the product; Rh D positive/negative - refers to blood type.

\(^a\)The magnitude of FMH should be assessed by a method capable of quantifying a haemorrhage of ≥6 mL of fetal red cells (equivalent to 12 mL of whole blood). Flow cytometry is accepted as the most accurate quantitative test for FMH and is the method of choice for quantitation if readily available (Refer to EOP11).
## Summary of guidance on the use and timing of Rh D immunoglobulin for routine immunoprophylaxis

<table>
<thead>
<tr>
<th>Clinical indication</th>
<th>Rh D immunoglobulin dose and timing</th>
<th>Target group</th>
<th>Relevant section of Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Routine immunoprophylaxis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Routine antenatal immunoprophylaxis</td>
<td>625 IU At 28 and 34 weeks of pregnancy</td>
<td>Rh D negative pregnant women with no preformed anti-D antibodies (unless NIPT for fetal RHD has predicted that they are not carrying an Rh D positive fetus)</td>
<td>3.1.1</td>
</tr>
<tr>
<td>Routine postnatal immunoprophylaxis</td>
<td>625 IU After giving birth</td>
<td>All Rh D negative women with no preformed anti-D antibodies after giving birth to an Rh D positive baby (based on cord blood or neonatal Rh D typing(^a)). If the baby is Rh D positive, administer Rh D immunoglobulin even if the NIPT predicted an Rh D negative baby. If the baby is Rh D positive and is born preterm, give the postnatal dose even if the birth is within 72 hours of a dose given for routine antenatal immunoprophylaxis or for a sensitising event. (^a) Cord blood or neonatal testing should be performed regardless of NIPT results for fetal RHD.</td>
<td>3.3.1</td>
</tr>
</tbody>
</table>

FMH: fetomaternal haemorrhage; IM: intramuscular; IU: international units; NIPT: non-invasive prenatal testing anti-D - refers to circulating antibodies; RHD - refers to genotype; Rh D immunoglobulin - refers to the product; Rh D positive/negative - refers to blood type.
Summary of guidance on the use and timing of Rh D immunoglobulin for sensitising event immunoprophylaxis

<table>
<thead>
<tr>
<th>Clinical indication</th>
<th>Rh D immunoglobulin dose and timing</th>
<th>Target group</th>
<th>Relevant section of Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sensitising event immunoprophylaxis</strong></td>
<td>------------------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Sensitising event immunoprophylaxis in the first 12 weeks of pregnancy</td>
<td>• Miscarriage&lt;br&gt;• Termination of pregnancy (medical after 10 weeks gestation or surgical)&lt;br&gt;• Ectopic pregnancy&lt;br&gt;• Molar pregnancy&lt;br&gt;• Chorionic villus sampling</td>
<td>250 IU&lt;br&gt;As soon as practical within 72 hours. If delayed beyond 72 hours, the dose should be given up to 10 days from the sensitising event, but may have lower efficacy&lt;br&gt;For ongoing uterine bleeding alone, a repeat dose of Rh D immunoglobulin (250 IU if before 12 weeks and 625 IU if after) may be appropriate after an interval of 6 weeks</td>
<td>All Rh D negative women with no preformed anti-D antibodies</td>
</tr>
<tr>
<td>Sensitising event immunoprophylaxis after 12^{rd} weeks of pregnancy</td>
<td>• Genetic studies (chorionic villus sampling, amniocentesis and cordocentesis)&lt;br&gt;• Abdominal trauma considered sufficient to cause fetomaternal haemorrhage, even if FMH testing is negative&lt;br&gt;• Each occasion of revealed or concealed antepartum haemorrhage. Where the woman suffers unexplained uterine pain the possibility of concealed antepartum haemorrhage (and the need for immunoprophylaxis) should be considered&lt;br&gt;• External cephalic version (successful or attempted)&lt;br&gt;• Miscarriage or termination of pregnancy</td>
<td>625 IU&lt;br&gt;As soon as practical within 72 hours. If delayed beyond 72 hours, the dose should be given up to 10 days from the sensitising event, but may have lower efficacy&lt;br&gt;For ongoing uterine bleeding alone, a repeat dose may be appropriate at 6 weekly intervals</td>
<td>All Rh D negative women with no preformed anti-D antibodies (unless NIPT for fetal RHD has predicted the fetus to be Rh D negative)</td>
</tr>
</tbody>
</table>
Clinical indication | Rh D immunoglobulin dose and timing | Target group | Relevant section of Guideline
--- | --- | --- | ---
Sensitising event immunoprophylaxis (cont.)

Large FMH ≥6 mL of fetal red cells (equivalent to 12 mL of whole blood)

- Antepartum
- Postpartum

| 625 IU as soon as possible
| Follow laboratory or specialist obstetric advice for additional doses of IM Rh D immunoglobulin or IV Rh D immunoglobulin, and for follow-up testing

All Rh D negative women with no preformed anti-D antibodies (unless NIPT for fetal RHD has predicted the fetus to be Rh D negative)

3.5.1

FMH: fetomaternal haemorrhage; IM: intramuscular; IU: international units; IV: intravenous; NIPT: non-invasive prenatal testing

anti-D - refers to circulating antibodies; RHD - refers to genotype; Rh D immunoglobulin - refers to the product;
Rh D positive/negative - refers to blood type

### Products available under the National Blood Arrangements

<table>
<thead>
<tr>
<th>Product</th>
<th>Presentation</th>
<th>Dose</th>
<th>Volume</th>
<th>Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rh(D) Immunoglobulin-VF</td>
<td>Single vial</td>
<td>250 IU</td>
<td>up to 2 mL</td>
<td>Slow deep intramuscular injection</td>
</tr>
<tr>
<td>Rh(D) Immunoglobulin-VF</td>
<td>Single vial</td>
<td>625 IU</td>
<td>up to 2 mL</td>
<td>Slow deep intramuscular injection</td>
</tr>
<tr>
<td>Rhophylac (imported)</td>
<td>Single use prefilled 2 mL syringe</td>
<td>1500 IU</td>
<td>2 mL</td>
<td>Intravenous or intramuscular injection Note: Available only where access to an intravenous preparation is required</td>
</tr>
</tbody>
</table>

Rh (D) Immunoglobulin-VF and Rhophylac are produced by CSL Behring and are distributed to approved health providers by Australian Red Cross Lifeblood (Lifeblood). For detailed product information, see the CSL Behring website.⁵

A current list of products available under the national blood arrangements is provided on the NBA website.⁶ This list is updated when products change; the list also shows the price of the products for the current financial year.

---


**Summary of recommendations and expert opinion points**

The Expert Reference Group (ERG) developed recommendations (Rs) where sufficient evidence was available from the systematic review of the literature. The recommendations have been carefully worded to reflect the strength of the body of evidence. Each recommendation has been given a grade in accordance with Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. The definitions of each grade are provided in Box 2.2 of Chapter 2.

The ERG also developed expert opinion points (EOPs) for material that was outside the scope of the systematic review, and for guidance that was amended or carried over from the 2003 Rh D immunoglobulin guidelines, and for which no new systematic review was conducted. The EOPs are based on consensus among the members of the ERG.

<table>
<thead>
<tr>
<th>Identifier</th>
<th>Guidance – recommendations and expert opinion points</th>
<th>Relevant section of Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blood group and antibody screening in all pregnant women</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EOP1</td>
<td>All women should have an ABO / Rh D type and antibody screen performed early in pregnancy. Rh D positive pregnant women do not require Rh D immunoglobulin.</td>
<td>3.1.1</td>
</tr>
<tr>
<td>EOP2</td>
<td>If antibody screening identifies anti-D in an Rh D negative pregnant woman, consideration of clinical history and laboratory findings is required to determine whether the anti-D is likely to be preformed (due to sensitisation) or passive (due to administration of Rh D immunoglobulin in the past 12 weeks). In cases of likely preformed anti-D antibodies, seek specialist obstetric advice, manage as Rh D sensitised and consider NIPT for fetal RHD status. see EOP3</td>
<td>1.1 3.1.1</td>
</tr>
<tr>
<td>EOP3</td>
<td>Rh D immunoglobulin should not be given to Rh D negative pregnant women with preformed anti-D antibodies. However, if it is unclear whether the anti-D detected in the mother’s blood is preformed (due to sensitisation) or passive (due to administration of Rh D immunoglobulin in the past 12 weeks), the treating clinician should be consulted. If there is continuing doubt, Rh D immunoglobulin should be administered.</td>
<td>3.1.1</td>
</tr>
</tbody>
</table>

<p>| <strong>Non-invasive prenatal testing for fetal RHD in all Rh D negative pregnant women</strong> | | |
| R9 | The ERG recommends the testing of maternal blood to determine fetal RHD genotype in all Rh D negative pregnant women to enable targeted antenatal Rh D immunoprophylaxis. (Strong recommendation, high certainty of evidence about the accuracy of the test) | 3.3.1 |
| R10 | The ERG recommends that test sensitivity be at least 99% in order to minimise the number of Rh D positive fetuses being missed by the test. (Strong recommendation, high certainty of evidence about the accuracy of the test) | 3.3.1 |
| R11 | The ERG recommends NIPT for fetal RHD from 11th weeks of pregnancy because of higher test accuracy than at earlier weeks. (Strong recommendation, high certainty of evidence about the accuracy of the test) | 3.3.1 |</p>
<table>
<thead>
<tr>
<th>Identifier</th>
<th>Guidance – recommendations and expert opinion points</th>
<th>Relevant section of Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Targeted immunoprophylaxis in Rh D negative pregnant women</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>R6</td>
<td>The ERG recommends that antenatal Rh D immunoprophylaxis in Rh D negative pregnant women with no preformed anti-D antibodies be targeted to those predicted to be carrying an Rh D positive fetus, based on NIPT for fetal RHD. This applies to both routine and sensitising event immunoprophylaxis, if the result of fetal RHD genotyping is available.(^a) (\text{(Strong recommendation, low certainty of evidence about the size of effect)})(^a) See EOP3 and EOP7</td>
<td>3.3.1</td>
</tr>
<tr>
<td>R7</td>
<td>If fetal Rh D status is not available or is uncertain, the ERG recommends that antenatal Rh D immunoprophylaxis be offered to Rh D negative pregnant women with no preformed anti-D antibodies. (\text{(Strong recommendation, low certainty of evidence about the size of effect)})</td>
<td>3.3.1</td>
</tr>
<tr>
<td><strong>Routine antenatal immunoprophylaxis in Rh D negative pregnant women</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>R1</td>
<td>The ERG recommends access to antenatal Rh D immunoglobulin for the prevention of Rh D alloimmunisation in Rh D negative pregnant women with no preformed anti-D antibodies.(^a) (\text{(Strong recommendation, low to very low certainty of evidence about the size of effect)})</td>
<td>3.1.1</td>
</tr>
<tr>
<td><strong>Routine dosage regimens in Rh D negative pregnant women</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>R2</td>
<td>The ERG recommends that administration of Rh D immunoglobulin 625 IU at 28 and 34 weeks of pregnancy(^a) continue in Rh D negative pregnant women with no preformed anti-D antibodies unless NIPT for fetal RHD(^b) has predicted that they are not carrying an Rh D positive fetus. The ERG does not currently suggest changing to a single dose of Rh D immunoglobulin 1500 IU. (\text{(Weak recommendation, low to very low certainty of evidence about the size of effect)})(^a) (\text{A woman’s pregnancy care schedule and clinical discretion may warrant the administration of Rh D immunoglobulin within 2 weeks before or after the recommended 28 and 34 weeks of pregnancy. However, if the second dose of Rh D immunoglobulin is given before 34 weeks and the pregnancy goes beyond the due date, the risk of inadequate anti-D coverage at birth increases.})(^a) All women should have an ABO/Rh D type and antibody screen performed early in pregnancy. Women who are Rh D negative should be retested at 28 weeks unless NIPT for fetal RHD has predicted that they are not carrying an Rh D positive fetus. The specimen should be collected before giving prophylactic Rh D immunoglobulin; however, the immunoglobulin can be given before the results are available.(^b)</td>
<td>3.1.1</td>
</tr>
<tr>
<td><strong>Sensitising event immunoprophylaxis in the first 12 weeks of pregnancy in Rh D negative women</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>R3</td>
<td>After the following sensitising events in the first 12 weeks of singleton or multiple pregnancy: miscarriage, termination of pregnancy (medical after 10 weeks’ gestation or surgical), ectopic pregnancy, molar pregnancy and chorionic villus sampling, the ERG recommends that a dose of Rh D immunoglobulin 250 IU be given to all Rh D negative women with no preformed anti-D antibodies to prevent Rh D alloimmunisation. (\text{(Strong recommendation, very low certainty of evidence about the size of effect)})</td>
<td>3.2.1</td>
</tr>
<tr>
<td>R4</td>
<td>In the setting of medical termination of pregnancy before 10 weeks of gestation there is insufficient evidence to suggest the routine use of Rh D immunoglobulin.(^a),(^4) (\text{(Discretionary (weak) recommendation, expert consensus)})</td>
<td>3.2.1</td>
</tr>
<tr>
<td>R5</td>
<td>In Rh D negative women with an ongoing pregnancy who have uterine bleeding in the first 12 weeks of pregnancy there is insufficient evidence to support the routine use of Rh D immunoglobulin. However, where the bleeding is repeated, heavy or associated with abdominal pain or significant pelvic trauma, immunoprophylaxis may be administered to women with no preformed anti-D antibodies. (\text{(Qualified (weak) recommendation, expert consensus)})</td>
<td>3.2.1</td>
</tr>
</tbody>
</table>
## Prophylactic use of Rh D immunoglobulin in pregnancy care

### Sensitising event immunoprophylaxis in the first 12 weeks of pregnancy in Rh D negative women (cont.)

<table>
<thead>
<tr>
<th>Identifier</th>
<th>Guidance – recommendations and expert opinion points</th>
<th>Relevant section of Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>EOP4</td>
<td>At all times when Rh D immunoglobulin is being administered for a sensitising event, it should be given as soon as practical within 72 hours. If delayed beyond 72 hours, the dose should be given up to 10 days from the sensitising event, but may have lower efficacy.</td>
<td>3.2.1</td>
</tr>
<tr>
<td>EOP5</td>
<td>For repeated sensitising events in the first 12 weeks of pregnancy, there is no evidence to guide practice. Specialist obstetric consultation is advised regarding further administration of Rh D immunoprophylaxis. For new sensitising events a repeated dose of Rh D immunoglobulin may be indicated. For ongoing uterine bleeding alone, a repeat dose of Rh D immunoglobulin (250 IU if during the first 12 weeks and 625 IU if after) may be appropriate after an interval of 6 weeks.</td>
<td>3.2.1</td>
</tr>
</tbody>
</table>

### Sensitising event immunoprophylaxis beyond the first 12 weeks of pregnancy in Rh D negative women

<table>
<thead>
<tr>
<th>Identifier</th>
<th>Guidance – recommendations and expert opinion points</th>
<th>Relevant section of Guideline</th>
</tr>
</thead>
</table>
| EOP7       | A dose of Rh D immunoglobulin 625 IU should be offered to every Rh D negative woman with no preformed anti-D antibodies, unless NIPT for fetal RHD has predicted the fetus to be Rh D negative, to ensure adequate protection against alloimmunisation for the following indications after 12-46 weeks of pregnancy:  
  - genetic studies (chorionic villus sampling, amniocentesis and cordocentesis)  
  - abdominal trauma considered sufficient to cause FMH, even if FMH testing is negative  
  - each occasion of revealed or concealed antepartum haemorrhage. Where the woman suffers unexplained uterine pain the possibility of concealed antepartum haemorrhage (and the need for immunoprophylaxis) should be considered  
  - external cephalic version (successful or attempted)  
  - miscarriage or termination of pregnancy. | 3.5.1 |
| EOP8       | For sensitising events after 20 weeks of pregnancy, the magnitude of FMH should be assessed, and further doses of Rh D immunoglobulin administered if required.  
  - a The first dose of the Rh D immunoglobulin should be given without waiting for the result of the test for FMH.  
  - b Taken from Point 4.3 of the BCSH Guidelines for the estimation of fetomaternal haemorrhage.  
  - c See Appendix C for guidance on dosing. | 3.5.1 |
| EOP9       | For ongoing uterine bleeding alone beyond 12 weeks’ gestation a further dose of Rh D immunoglobulin (625 IU) may be appropriate at 6 weekly intervals.  
  - New sensitising events should be managed with a further dose of Rh D immunoglobulin (625 IU) and assessment of FMH (after 20 weeks or where otherwise indicated) with additional dosing to cover large volume FMH if required (100 IU for each mL of fetal red cells beyond 6 mL).  
  - a See Appendix C for guidance on dosing. | 3.5.1 |
<p>| EOP10      | In reference to antenatal sensitising events after 20 weeks of pregnancy and after giving birth, a maternal sample to assess the volume of FMH should be taken before administration of Rh D immunoglobulin. However, at no time should Rh D immunoglobulin be delayed based on, or pending, the results of testing to quantitate FMH. Between 13 and 20 weeks of pregnancy, the magnitude of FMH may be assessed at clinical discretion. | 3.5.1 |</p>
<table>
<thead>
<tr>
<th>Identifier</th>
<th>Guidance – recommendations and expert opinion points</th>
<th>Relevant section of Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>EOP11</td>
<td>The magnitude of the FMH should be assessed by a method capable of quantifying a haemorrhage of ≥6 mL of fetal red cells (equivalent to 12 mL of whole blood). Flow cytometry is accepted as the most accurate quantitative test for FMH and is the method of choice for quantitation if readily available. Where FMH quantitation shows that FMH greater than that covered by the dose already administered has occurred, an additional dose or doses of Rh D immunoglobulin sufficient to provide immunoprophylaxis must be administered as soon as practical within 72 hours. If delayed beyond 72 hours, the dose should be given up to 10 days from the sensitising event, but may have lower efficacy.</td>
<td>3.5.1</td>
</tr>
<tr>
<td>EOP12</td>
<td>For large bleeds ≥ 6 mL of fetal red cells (equivalent to 12 mL of whole blood), follow-up testing should be performed on a sample collected 48 hours post intravenous Rh D immunoglobulin administration or 72 hours post intramuscular Rh D immunoglobulin administration, to determine whether further dosing is required. Supplemental Rh D immunoglobulin should be administered if the test for FMH is still positive. If testing for fetal cells is negative on a follow-up sample, no further testing is required.</td>
<td>3.5.1</td>
</tr>
</tbody>
</table>

**Targeted immunoprophylaxis in postnatal Rh D negative women**

| R8         | The ERG currently **recommends** that postnatal Rh D immunoprophylaxis (Rh D immunoglobulin 625 IU) continue to be administered to all Rh D negative women with no preformed anti-D antibodies who have a baby who is predicted to be Rh D positive based on NIPT for fetal **RHD**, or cord blood or neonatal Rh D typing. The cord blood or neonatal testing should be performed regardless of the results of NIPT for fetal **RHD**, but need not delay administration of Rh D immunoprophylaxis when the fetus has been shown to be **RHD** positive by NIPT testing. If the baby is Rh D positive, administer Rh D immunoglobulin even if the NIPT predicted an Rh D negative baby. (Strong recommendation, high certainty of evidence) | 3.3.1 |

**High BMI**

| R12        | The ERG **does not currently support** an increased dose of Rh D immunoglobulin or changes in laboratory testing on the basis of high BMI in Rh D negative pregnant women. (Weak recommendation, very low certainty of evidence about the size of effect) | 3.4.1 |
| EOP6       | Rh D immunoglobulin must be given by deep intramuscular injection. For women with a BMI of more than 30, particular consideration should be given to factors that may affect the adequacy of the injection (e.g. the site of administration and the length of the needle used). | 3.4.1 |

**Notes:**
- BMI: body mass index; EOP: expert opinion point; ERG: Expert Reference Group; FMH: fetomaternal haemorrhage; IU: international units; NIPT: non-invasive prenatal testing; R: recommendation.
- anti-D - refers to circulating antibodies; **RHD** - refers to genotype; Rh D immunoglobulin - refers to the product; Rh D positive/negative - refers to blood type.
1 Introduction

1.1 Background

Maternal Rh D antibodies may develop during pregnancy when an Rh D negative pregnant woman carries an Rh D positive fetus. Development of antibodies occurs when fetal red blood cells (RBCs) enter the maternal circulation, and antibodies are produced towards the fetal Rh D antigen. The most common sources of fetal RBCs entering the maternal circulation are thought to be small fetomaternal haemorrhages (FMHs) at birth and silent transplacental haemorrhages in the antenatal period.9-11 The maternal response to the fetal RBCs is known as ‘sensitisation’ or alloimmunisation. No apparent adverse health outcomes occur in the mother as a result of this sensitisation; however, haemolytic disease of the fetus and newborn (HDFN) can arise in an Rh D positive fetus (usually in subsequent pregnancies).

HDFN occurs when maternal antibodies cross the placenta into the baby’s circulation and mediate destruction of the baby’s RBCs. This destruction causes fetal anaemia (a shortage of RBCs, which are required to carry oxygen), and can lead to hyperbilirubinaemia (elevated levels of bilirubin, a waste product of the degraded RBCs) and jaundice (yellowing of the skin and whites of the eyes). In severe cases, the HDFN causes hydrops fetalis (gross oedema or accumulation of fluid leading to fetal death) or kernicterus (a form of brain damage).9, 11, 12 In the absence of intervention, HDFN affects 1% of neonates, and is a significant cause of perinatal mortality and morbidity, and long-term disability.9, 10

Rh D immunoglobulin is manufactured from plasma of Rh D negative blood donors who are stimulated to produce elevated levels of anti-D antibodies. It is given to Rh D negative women with no preformed anti-D antibodies (during pregnancy and immediately postpartum) to prevent Rh D alloimmunisation. In Australia, about 17% of blood donors are Rh D negative.13 This blood type is highest in those who are of European origin (16%), less common in those of African origin (7%), and rare in Indigenous peoples and those of East Asian origin (<1%). In the United Kingdom (UK), it is estimated that 10% of live births are Rh D positive babies delivered to Rh D negative women10; however, this number may be higher in the Australian setting.14

Before Rh D immunoprophylaxis became available in the late 1960s, approximately 16% of women who had given birth to an Rh D positive, ABO compatible baby developed alloantibodies in their first susceptible pregnancy.9 The risk of alloimmunisation increased with the number of susceptible pregnancies. Alloimmunisation can still occur, albeit at a lower rate if the mother and baby are ABO incompatible, and it can still result in severe HDFN.15 Without immunoprophylaxis, the overall risk when considering both ABO compatible and incompatible mother-baby pairs was estimated at about 13%. As a result, in the first two thirds of the 20th century, HDFN was estimated to affect as many as 1 in 100 women, causing death of the fetus or newborn in 20% of first affected and 40% of subsequently affected pregnancies.9

Clinical trials demonstrated that Rh D immunoprophylaxis given immediately after birth decreases the risk about 10-fold to approximately 1%, results supported by observational studies.17, 18 Adding antenatal immunoprophylaxis may reduce the risk to about 0.2%.12 As a result of programs of immunoprophylaxis, HDFN has gone from being a leading cause of fetal and neonatal illness and death19 to a very uncommon one. Although, in the remaining affected pregnancies, life-threatening and disabling consequences of HDFN can usually be prevented by skilled contemporary clinical care9, 20, the burdens of increased diagnostic testing in pregnancy are significant, even if the HDFN is mild.
In moderate or severe HDFN the maternal and neonatal burden of investigation and management are substantial, indicating that there is high value in continuing successful programs of prevention.

When anti-D is identified in a positive routine prenatal antibody screening test, it is essential to determine whether this anti-D is preformed (by a maternal immune response to previous exposure to the Rh D antigen) or passive (through the recent administration of Rh D immunoglobulin). This differentiation is important for the appropriate management of the pregnant woman and requires consideration of clinical history and laboratory findings. The clinician responsible for management of the pregnant woman should discuss the antibody screen results with the laboratory if necessary. Routine Rh D immunoglobulin prophylaxis should be recommended unless it is certain that the anti-D is preformed.21

1.2 The national prophylaxis program

The National Health and Medical Research Council’s (NHMRC’s) 1999 Guidelines on the prophylactic use of Rh D immunoglobulin (anti-D) in obstetrics22 were updated by the National Blood Authority (NBA) in 20031, with the aim of informing clinicians, other health professionals and policy makers of new recommendations for the staged implementation of full antenatal prophylaxis with Rh D immunoglobulin in Australia. The 2003 Rh D immunoglobulin guidelines2 also included a strategy to enable the staged introduction of antenatal prophylaxis in the short term, while working towards self-sufficiency in the longer term.

Stage 1 of the national program for prophylaxis commenced in November 2002; it covered routine antenatal prophylaxis at 28 and 34 weeks’ gestation for Rh D negative women without preformed anti-D antibodies having their first baby, and sensitising event prophylaxis for Rh D negative women without preformed anti-D antibodies. During this stage, an imported Rh D immunoglobulin product was used for postnatal prophylaxis. Stage 2 commenced in January 2005, with routine antenatal prophylaxis at 28 and 34 weeks’ gestation being extended to all Rh D negative women without preformed anti-D antibodies. During this stage, an imported Rh D immunoglobulin product was still required for postnatal prophylaxis. Stage 3 commenced in March 2006, with both antenatal and postnatal Rh D prophylaxis being fully supported by Australian-sourced Rh D immunoglobulin.

1.3 Clinical need for this guideline

Key Australian guidance has been published since 2003, including two publications from 2015: Guidelines for the use of Rh (D) immunoglobulin (anti-D) in obstetrics in Australia23 and Expert panel consensus position statement regarding the use of Rh(D) immunoglobulin in patients with a body mass index ≥30.24

In September 2016, the NBA commenced a scoping exercise to identify clinical guidance published since the release of the 2003 Rh D immunoglobulin guidelines.1 The aim was to ensure that Australia’s clinical guidance and antenatal prophylaxis program still reflect current evidence and best clinical practice.

The scoping exercise found that a number of international guidelines on the prophylactic use of Rh D immunoglobulin have been published since 2003.8,25-34 However, the recommendations for application and administration of Rh D immunoglobulin within this guidance was not consistent.5

As discussed in Appendix 1 of Volume 1 of the accompanying technical report.25
The exercise also found that the 2003 Rh D immunoglobulin guidelines\(^1\) do not address a number of issues that have emerged since publication; for example, alternative dosage regimens, non-invasive prenatal testing (NIPT) for fetal RHD and the use of Rh D immunoglobulin in women with high body mass index (BMI).

These findings were shared with the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG), and it was agreed that the NBA and RANZCOG should collaborate to develop a new evidence-based guideline.

A multidisciplinary Expert Reference Group (ERG) with expertise from a range of clinical settings was established to identify the key issues that should be investigated for a new evidence-based guideline on the prophylactic use of Rh D immunoglobulin in pregnancy care. The following key areas of concern were identified:

1. Does the available evidence still support universal\(^4\) routine antenatal prophylaxis?
2. Should universal routine antenatal prophylaxis be moved from a two-dose regimen to a one-dose regimen?\(^6\)
3. Should the list of sensitising events in the first 12 weeks of pregnancy be amended to include additional events?\(^7\)
4. To reduce unnecessary use of Rh D immunoglobulin, should non-invasive prenatal screening be used in the first trimester so that prophylaxis can be targeted?
5. Does increasing BMI impact on the efficacy of Rh D immunoglobulin?\(^8\)

### 1.4 Intent of the guideline

The intent of the guideline is to provide updated clinical guidance on the prophylactic use of Rh D immunoglobulin in pregnancy care in accordance with current evidence and consensus among clinical experts. It is targeted at health care professionals involved in the management of pregnant Rh D negative women.

### 1.5 Structure of the guideline

This document contains:

- a summary of the clinical guidance, in the form of recommendations (Rs) and expert opinion points (EOPs)
- an introduction, outlining the background to the issue and the current antenatal prophylaxis program, the clinical need for this document and guidance transferred from the 2003 guidelines\(^1\) (Chapter 1)
- a summary of the systematic review process and the process by which evidence has been translated into clinical guidance (Chapter 2)
- the clinical guidance developed by the ERG (Chapter 3).

---

\(^{4}\) That is, in all pregnant women who are Rh D negative with no preformed anti-D antibodies.

\(^{6}\) In June 2010, an Australian Rh (D) Joint Consultative Committee (JCC) considered the available evidence and the relative advantages and disadvantages of different regimens, and strongly supported the move to a single-dose regimen.

\(^{7}\) The quality of available evidence assessed in the 2003 guideline was very low.

\(^{8}\) An Expert Panel was convened in May 2015 and the draft Consensus Statement indicates that there is still uncertainty around this issue.\(^24, 36\)
A set of appendices provide information on the structure of the ERG and the process for developing this guideline.

1.6 Related material

The technical report that underpins this document is available from the NBA website\(^h\) in two volumes:

- Volume 1 contains background information and the results of the systematic reviews pertaining to the clinical questions posed within this guideline\(^a\).
- Volume 2 contains appendixes that document the literature searches and critical appraisal of the studies\(^b\).

\(^h\) See \url{www.blood.gov.au}
2 Methodology

These evidence-based clinical practice guidelines were developed by following the principles proposed by the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Working Group. The process involved developing a set of research questions, systematically reviewing the scientific literature for evidence related to those questions, and then developing and grading recommendations based on a structured assessment of the evidence. The methods used to apply this process are outlined in this chapter and are given in full in the accompanying technical reports, which present in detail the methodology used to identify the evidence base (clinical questions addressed, systematic literature search undertaken, and inclusion and exclusion criteria described), the characteristics and quality of the evidence base (data extraction and risk of bias forms), and detailed results presented by outcome (evidence summary tables and GRADE profiles).

The systematic review process was based on that described in the Cochrane handbook for systematic reviews of interventions. Covidence, a web-based platform for producing systematic reviews was used to store data that are compatible with the Cochrane data collection tools. RevMan was used for the main analyses, and GRADEpro GDT software was used to record decisions and derive an overall GRADE (high, moderate, low or very low) for the certainty of evidence for each outcome.

2.1 Question development

Between September 2016 and October 2017, relevant clinical research questions for these guidelines were identified, developed and prioritised by a multidisciplinary ERG, working with an independent systematic review expert and the NBA. The four main clinical questions (and two subquestions) chosen for evidence review are listed in Box 2.1, and were structured according to PICO (population, intervention, comparator and outcome) criteria.

A research protocol was then developed that described the methodology used to source the clinical evidence (a systematic search of the literature), select the best available evidence, critically appraise and present the evidence, and determine the quality of the evidence base for each question, using a structured assessment of the body of evidence in accordance with GRADE methodology.

2.2 Systematic review process

To identify the evidence base for the four clinical questions detailed in Box 2.1, a systematic search of published medical literature was conducted. Characteristics of the ideal evidence base specific to each question were based on guidance from the NHMRC levels of evidence. A systematic review of Level II studies was considered the highest level of evidence (Level I) for all question types. The review considered both peer-reviewed and unpublished and grey literature. Ongoing trials and studies published as abstracts only were also included if they provided sufficient information for the outcome of interest.

---

1 Available at www.gradeworkinggroup.org
2 Available at www.covidence.org
4 Available at www.gradepro.org
The systematic review was conducted using a stepped process in which the highest level body of evidence was assessed before lower levels of evidence were considered. Further assessment down to Level IV was not conducted for any research question, irrespective of whether insufficient higher level evidence was found to address all critical and important outcomes for that question. This is because it is difficult (if not impossible) to attribute observed changes in outcomes at this level.

2.3 Literature search

The search strategy was developed in Ovid (for Embase and Medline), based on key elements provided in the research questions. The primary databases searched were Embase, Medline, CINAHL Plus, the Cochrane Library and PubMed (limited to in-process citations and citations not indexed in Medline). Additional searches were conducted on clinical trial registries, health technology assessment and guideline websites (e.g. the National Institutes of Health and Care Excellence), and literature sources recommended by expert members of the ERG. Details of the systematic literature search are provided in Volume 2 of the technical report.37

The search strategy was not limited by language; however, publications in languages other than English were only considered where a full text translation into English was available. No date or geographic limitations were applied when conducting the search. A literature search start date of 2002, defined by the ERG for Question 1, was applied once citations had been imported into the bibliographic management database.

2.4 Formulating recommendations

A consensus process (see Appendix E) was used to ensure that the clinical guidance was consistent with the evidence presented. GRADE profiles and summaries of findings were used to inform translation of the evidence into recommendations for use in the clinical guidance chapter (Chapter 3). Evidence-to-decision tables provided in the GRADEpro GDT software were used to guide this process.42 Recommendations were based on four key concepts: balance of benefits and risks, values and preferences, resource use and quality of evidence. Recommendations were carefully worded to ensure that the recommended action was clear, as described in Box 2.2.

Where there was insufficient quantity or certainty of evidence to develop evidence-based recommendations, the ERG developed EOPs through consensus. Areas that were not subject to a systematic review, but where it was considered important to offer clinical guidance, were also addressed as EOPs, developed through expert consensus.
Box 2.1  Systematic review questions

**Question 1** – In Rh D negative pregnant women with no preformed anti-D, does universal routine antenatal prophylaxis with Rh D immunoglobulin (one or two doses) prevent Rh D alloimmunisation?

**Question 1 (subquestion)** – In Rh D negative pregnant women with no preformed anti-D, is universal routine antenatal prophylaxis with one dose of Rh D immunoglobulin as effective at preventing Rh D alloimmunisation as universal routine prophylaxis with two doses of Rh D immunoglobulin?

**Question 2** – In Rh D negative women with no preformed anti-D who have experienced one of the following first trimester sensitising events – abdominal trauma, molar pregnancy, ectopic pregnancy, spontaneous miscarriage, threatened miscarriage or medical termination of pregnancy (with or without a curette), does universal first trimester sensitising event prophylaxis with Rh D immunoglobulin prevent Rh D alloimmunisation?

**Question 3** – In Rh D negative pregnant women with no preformed anti-D, does targeted routine antenatal or sensitising event prophylaxis to women with an Rh D positive fetus increase the incidence of Rh D alloimmunisation compared with universal routine antenatal or sensitising event prophylaxis?

**Question 3 (subquestion)** – In Rh D negative pregnant women with no preformed anti-D, what is the diagnostic accuracy of non-invasive prenatal screening to identify fetal Rh D status?

**Question 4** – In Rh D negative pregnant or postpartum women with no preformed anti-D, does increasing BMI increase the risk of failure of anti-D administration?

Box 2.2  Definition of the strength of recommendations

**Strong recommendation** (for or against) – the guideline panel is confident that the desirable effects of an intervention outweigh its undesirable effects.

**Weak recommendation** (for an action) – the desirable effects *probably* outweigh the undesirable effects (for an intervention) but appreciable uncertainty exists. Recommendation is influenced by a woman’s values, resources available and/or setting.

**Weak recommendation** (against an action) – the undesirable effects *probably* outweigh the desirable effects but appreciable uncertainty exists. Recommendation is influenced by a woman’s values, resources available and/or setting.

**Discretionary (weak) recommendation** – the desirable effects *probably* outweigh the undesirable effects (for an intervention) but appreciable uncertainty exists. Action may be discretionary based on opinion of a woman or practitioner.

**Qualified (weak) recommendation** – the desirable effects *probably* outweigh the undesirable effects (for an intervention) but appreciable uncertainty exists. An explanation regarding the issues that would lead to different decisions is offered.
2.5 Study selection

All potentially relevant studies were identified after applying prespecified inclusion and exclusion criteria, as outlined in Volume 1 of the technical report. The study selection process was completed by one systematic reviewer, with a second reviewer crosschecking the screening process to ensure adherence to the prespecified exclusion criteria. Any differences were resolved by discussion with a third reviewer (with advice sought from the ERG as necessary) to confirm study eligibility.

Briefly, Questions 1–3 included pregnant women who were Rh D negative and did not have preformed anti-D antibodies. The focus of these questions was antenatal prophylaxis (i.e. during pregnancy) with Rh D immunoglobulin. Question 4 included women who were Rh D negative with no preformed anti-D antibodies receiving prophylaxis either during pregnancy or postpartum (after the birth of an Rh D positive baby). There were no restrictions on the product type, mode of administration, number of doses or dosage.

There were no limits to age, race or nationality, but studies were to be set in countries with health systems broadly comparable to those in Australia especially in terms of the health care facilities and resourcing. Studies set in low or middle-income countries were identified for consideration by the ERG; however, unless there was additional information demonstrating that the population or setting was comparable to Australia, these studies were excluded.

For Question 3, to provide targeted prophylaxis, identification of an Rh D positive fetus is required. The prenatal tests were to be non-invasive (i.e. a simple blood test that uses maternal blood to determine the fetal Rh D status), but there were no restrictions on the timing, product type or testing methodology.

The critical outcome measure for all questions was the incidence of Rh D alloimmunisation. Additional data to be extracted related to timing of the event (i.e. during pregnancy, postpartum or in subsequent pregnancies). Other outcome measures included the incidence of a positive test for FMH (any test that detected fetal cells in the maternal blood), utilisation rates of Rh D immunoglobulin and any adverse event (mild, moderate or severe).

2.6 Strength and limitations of the evidence

The methodological quality of included studies was assessed, and relevant data were extracted into data extraction tables by one systematic reviewer. For each study, the most appropriate risk of bias assessment tool (based on study design) was used, with a summary judgement provided in relation to the clarity and completeness or reporting, methods and processes, as well as the underlying assumptions and limitations. Available effect estimates (95% confidence intervals [CI], p-values) were presented in tables structured by PICO criteria and study design. These data were then crosschecked by a second reviewer and summarised into appropriate categories or subquestions, according to the key research question.

GRADE evidence profiles were then developed for each comparison and outcome, with relevance to the Australian context considered at this time.

---

For example, Canada, Europe, New Zealand, the United Kingdom and the United States of America.
The body of evidence was consolidated and rated across five key domains:\footnote{40}: 

- **risk of bias** – based on the summary assessment across studies for each outcome reported for a comparison
- **inconsistency** – based on heterogeneity in the observed intervention effects across studies that suggests important differences in the effect of the intervention, and whether this can be explained
- **imprecision** – based on interpretation of the upper and lower confidence limits, and whether the intervention has a clinically important effect
- **indirectness** – based on important differences between the review questions and the characteristics of included studies that may lead to important differences in the intervention effects
- **publication bias** – based on the extent to which the evidence is available; such bias would be suspected when the evidence is limited to a small number of small trials.

For each domain, a judgement was made about whether there were serious, very serious or no concerns, resulting in an overall grade (high, moderate, low or very low) for the certainty of evidence for each outcome. Scoring of the certainty of the evidence began as ‘high’ for randomised trials (score=4) and was downgraded by –1 for each domain with serious concerns, or –2 for very serious concerns, with observational studies being a ‘low’. Footnotes were used to record judgements made by the ERG about downgrading (or upgrading) of the evidence. Further information is detailed in Volume 2 of the technical report.
3 Clinical guidance

3.1 Routine antenatal Rh D immunoprophylaxis

Question 1 – (Intervention)
In Rh D negative pregnant women with no preformed anti-D, does universal routine antenatal prophylaxis with Rh D immunoglobulin (one or two doses) prevent Rh D alloimmunisation?

Subquestion 1 – (Intervention)
In Rh D negative pregnant women with no preformed anti-D, is universal routine antenatal prophylaxis with one dose of Rh D immunoglobulin as effective at preventing Rh D alloimmunisation as universal routine prophylaxis with two doses of Rh D immunoglobulin?

Rh D immunoglobulin is given antenatally and immediately postpartum to prevent Rh D alloimmunisation in Rh D negative pregnant women with no preformed anti-D antibodies. The literature search for this question aimed to establish whether administration of Rh D immunoglobulin should be routine in the third trimester of pregnancy, and whether one dose at 28 weeks of pregnancy is as effective as two smaller doses at 28 and 34 weeks of pregnancy. The review examined routine third trimester antenatal anti-D prophylaxis (RAADP) in either one or two doses, looking at the effect on detectable FMHs, HDFN and Rh D alloimmunisation during pregnancy, after birth or in a subsequent pregnancy.
3.1.1 Recommendations and Expert Opinion Points

<table>
<thead>
<tr>
<th>Identifier</th>
<th>Guidance – recommendations and expert opinion points</th>
</tr>
</thead>
<tbody>
<tr>
<td>EOP1</td>
<td>All women should have an ABO / Rh D type and antibody screen performed early in pregnancy. Rh D positive pregnant women do not require Rh D immunoglobulin.</td>
</tr>
</tbody>
</table>
| R1         | The ERG recommends access to antenatal Rh D immunoglobulin for the prevention of Rh D alloimmunisation in Rh D negative pregnant women with no preformed anti-D antibodies.\(^4\)
   (Strong recommendation, low to very low certainty of evidence about the size of effect)\(^a\)
| R2         | The ERG recommends that administration of Rh D immunoglobulin 625 IU at 28 and 34 weeks of pregnancy\(^a\) continue in Rh D negative pregnant women with no preformed anti-D antibodies unless NIPT for fetal RHD\(^b\) has predicted that they are not carrying an Rh D positive fetus. The ERG does not currently suggest changing to a single dose of Rh D immunoglobulin 1500 IU.
   (Weak recommendation, low to very low certainty of evidence about the size of effect)
   \(^a\) A woman’s pregnancy care schedule and clinical discretion may warrant the administration of Rh D immunoglobulin within 2 weeks before or after the recommended 28 and 34 weeks of pregnancy. However, if the second dose of Rh D immunoglobulin is given before 34 weeks and the pregnancy goes beyond the due date, the risk of inadequate anti-D coverage at birth increases.
   \(^b\) All women should have an ABO/Rh D type and antibody screen performed early in pregnancy. Women who are Rh D negative should be retested at 28 weeks unless NIPT for fetal RHD has predicted that they are not carrying an Rh D positive fetus. The specimen should be collected before giving prophylactic Rh D immunoglobulin; however, the immunoglobulin can be given before the results are available.\(^2\) |
| EOP2       | If antibody screening identifies anti-D in an Rh D negative pregnant woman, consideration of clinical history and laboratory findings is required to determine whether the anti-D is likely to be preformed (due to sensitisation) or passive (due to administration of Rh D immunoglobulin in the past 12 weeks).\(^a\) In cases of likely preformed anti-D antibodies, seek specialist obstetric advice, manage as Rh D sensitised and consider NIPT for fetal RHD status.
   \(^a\) See EOP3 |
| EOP3       | Rh D immunoglobulin should not be given to Rh D negative pregnant women with preformed anti-D antibodies. However, if it is unclear whether the anti-D detected in the mother’s blood is preformed (due to sensitisation) or passive (due to administration of Rh D immunoglobulin in the past 12 weeks), the treating clinician should be consulted. If there is continuing doubt, Rh D immunoglobulin should be administered. |

EOP: Expert Opinion Point; ERG: Expert Reference Group; IU: international units; NIPT: Non-invasive prenatal testing; R: recommendation

3.1.2 Background

The aim of Question 1 was to update the evidence base regarding universal administration of RAADP at 28 and 34 weeks of pregnancy in Rh D negative women. RAADP is aimed at all pregnant women who are Rh D negative with no preformed anti-D antibodies. A subquestion to assess whether the two-dose strategy can be replaced with a single-dose strategy was also included.
3.1.3 Summary of evidence

Summary of evidence – Question 1

The evidence for Question 1 is summarised in Table 3.1.

Table 3.1 Summary of findings – Question 1

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>No of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence of Rh D alloimmunisation (any timepoint)</td>
<td>14 per 1000</td>
<td>5 per 1000 (1 to 22)</td>
<td>RR 0.39 (0.09 to 1.63)</td>
<td>2297 (2 RCTs)</td>
<td>In Rh D negative women with no preformed anti-D, universal RAADP may reduce the incidence of Rh D alloimmunisation (1 or 2 doses, any timepoint) but we are uncertain about the size of the effect.</td>
</tr>
<tr>
<td>Incidence of Rh D alloimmunisation (any timepoint)</td>
<td>11 per 1000</td>
<td>3 per 1000 (2 to 6)</td>
<td>RR 0.31 (0.18 to 0.54)</td>
<td>51 987 (8 observational studies)</td>
<td>In Rh D negative women with no preformed anti-D, universal RAADP may reduce the incidence of Rh D alloimmunisation (1 or 2 doses, any timepoint) but we are uncertain about the size of the effect.</td>
</tr>
<tr>
<td>Incidence of Rh D alloimmunisation (in subsequent pregnancy)</td>
<td>8 per 1000</td>
<td>3 per 1000 (2 to 5)</td>
<td>RR 0.43 (0.31 to 0.59)</td>
<td>31 826 (6 observational studies)</td>
<td>In Rh D negative women with no preformed anti-D, universal RAADP may reduce the incidence of Rh D alloimmunisation (in a subsequent pregnancy) but we are uncertain about the size of the effect.</td>
</tr>
<tr>
<td>Incidence of Rh D alloimmunisation (during pregnancy)</td>
<td>6 per 1000</td>
<td>2 per 1000 (0 to 8)</td>
<td>RR 0.33 (0.08 to 1.37)</td>
<td>28 357 (4 observational studies)</td>
<td>In Rh D negative women with no preformed anti-D, universal RAADP may reduce the incidence of Rh D alloimmunisation (during pregnancy) but we are very uncertain about the size of the effect.</td>
</tr>
<tr>
<td>Incidence of Rh D alloimmunisation (at birth of Rh D positive newborn or within three days of delivery)</td>
<td>14 per 1000</td>
<td>3 per 1000 (1 to 6)</td>
<td>RR 0.19 (0.08 to 0.45)</td>
<td>24 622 (8 observational studies)</td>
<td>In Rh D negative women with no preformed anti-D, universal RAADP may reduce the incidence of Rh D alloimmunisation (at birth or within three days of delivery of an Rh D positive newborn) but we are very uncertain about the size of the effect.</td>
</tr>
</tbody>
</table>
In Rh D negative pregnant women with no preformed anti-D, does universal routine antenatal prophylaxis with Rh D immunoglobulin (one or two doses) prevent Rh D alloimmunisation?

**Patient or population:** Rh D negative pregnant women with no preformed anti-D

**Setting:** Obstetrics and maternity, primary

**Intervention:** Universal antenatal Rh D immunoprophylaxis (1 or 2 doses)

**Comparison:** Placebo or no universal antenatal Rh D immunoprophylaxis

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>Ne of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence of Rh D alloimmunisation (up to 12 months postnatal follow-up)</td>
<td>15 per 1000 (2 to 4)</td>
<td>RR 0.19 (0.13 to 0.29)</td>
<td>17372 (8 observational studies)</td>
<td>☀️ ☀️ ☀️ LOW</td>
<td>In Rh D negative women with no preformed anti-D, universal RAADP may reduce the incidence of Rh D alloimmunisation (up to 12 months after the birth of an Rh D positive newborn) but we are uncertain about the size of the effect.</td>
</tr>
<tr>
<td>Incidence of a positive test for FMH assessed with: Kleihauer test at 32 to 35 weeks of pregnancy</td>
<td>70 per 1000 (29 to 62)</td>
<td>RR 0.60 (0.41 to 0.88)</td>
<td>1884 (1 RCT)</td>
<td>☀️ ☀️ ☀️ MODERATE</td>
<td>In Rh D negative women with no preformed anti-D, universal RAADP (1 or 2 doses) likely reduces the incidence of a positive test for FMH (assessed at 32–35 weeks of pregnancy).</td>
</tr>
<tr>
<td>Incidence of a positive test for FMH assessed with: Kleihauer test at birth of Rh D positive newborn</td>
<td>202 per 1000 (93 to 159)</td>
<td>RR 0.60 (0.46 to 0.79)</td>
<td>1189 (1 RCT)</td>
<td>☀️ ☀️ ☀️ MODERATE</td>
<td>In Rh D negative women with no preformed anti-D, universal RAADP (1 or 2 doses) likely reduces the incidence of a positive test for FMH (assessed at birth of an Rh D positive newborn).</td>
</tr>
<tr>
<td>Adverse neonatal events: jaundice</td>
<td>4 per 1000 (0 to 10)</td>
<td>RR 0.26 (0.03 to 2.30)</td>
<td>1882 (1 RCT)</td>
<td>☀️ ☀️ ☀️ LOW</td>
<td>In Rh D negative women with no preformed anti-D, the effect of universal RAADP (1 or 2 doses) on neonatal jaundice is uncertain.</td>
</tr>
<tr>
<td>Adverse neonatal events: prevalence of severe HDFN (perinatal mortality, need for IUT and/or exchange transfusion)</td>
<td>2 per 1000 (0 to 2)</td>
<td>RR 0.51 (0.09 to 0.92)</td>
<td>21221 (1 observational study)</td>
<td>☀️ ☀️ ☀️ VERY LOW</td>
<td>In Rh D negative women with no preformed anti-D, the effect of universal RAADP (1 or 2 doses) on severe adverse neonatal events is very uncertain.</td>
</tr>
</tbody>
</table>
In Rh D negative pregnant women with no preformed anti-D, does universal routine antenatal prophylaxis with Rh D immunoglobulin (one or two doses) prevent Rh D alloimmunisation?

**Patient or population:** Rh D negative pregnant women with no preformed anti-D

**Setting:** Obstetrics and maternity, primary

**Intervention:** Universal antenatal Rh D immunoprophylaxis (1 or 2 doses)

**Comparison:** Placebo or no universal antenatal Rh D immunoprophylaxis

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>N of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse maternal events attributed to Rh D immunoprophylaxis</td>
<td>None of the identified studies reported any serious adverse events. A few cases of mild pain, soreness, and itching at the injection site noted. One study reported marked flushing and mild chest pain that was attributed to a specific batch study drug. (Pilgrim et al. (2009) and McBain et al. (2015))</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>In Rh D negative women with no preformed anti-D, the effect of universal RAADP (1 or 2 doses) on adverse maternal events is unknown.</td>
</tr>
</tbody>
</table>

*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; FMH: fetomaternal haemorrhage; GRADE: Grading of Recommendations Assessment, Development and Evaluation; HDFN: haemolytic disease of the fetus and newborn; IUT: intrauterine transfusion; RAADP: routine antenatal anti-D prophylaxis; RCT: randomised controlled trial; RR: risk ratio

**GRADE Working Group grades of evidence**

**High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect

**Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

**Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

**Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

**Explanations**

a. One or more randomised studies with plausible bias that raises serious doubts about the results.
b. Missing data and exclusion of some women may overestimate the clinical effectiveness of RAADP.
c. Includes one quasi-randomised trial with high risk of selection bias.
d. No significant heterogeneity, with variability in effect estimates assessed as moderate ($I^2$ statistic between 25% and 50%). Does not reduce confidence in results to inform decision making.
e. Obstetric practice and the baseline characteristics of the population may not be reflective of current practice; however, this was considered not to seriously affect the confidence in the observed effect and could be sensibly applied.
f. Low event rate and/or wide CIs that cross the line of no effect. Confidence in the results is weak.
g. One or more comparative observational studies with some important problems that seriously weaken the confidence in the results.
h. Studies include historical and/or geographic controls, and it is not clear whether intervention and control groups are comparable at baseline.
i. Significant heterogeneity with substantial variability in effect estimates ($I^2$ statistic >50%). Reduces confidence in the results to inform decision making.
j. No significant heterogeneity ($I^2$ statistic = 0%).
k. Includes one RCT and one quasi-RCT.
l. Includes one RCT, one quasi-RCT and six observational studies. One observational study does not contribute any data.
m. Includes one RCT, one quasi-RCT and six observational studies. Two observational studies do not contribute any data.
n. One study only. Heterogeneity not assessed.
o. One or two comparative observational studies that appear to provide sound evidence for a nonrandomised study but cannot be considered comparable to a well-performed RCT.
p. Some concerns with reporting bias and missing data.
Summary of evidence – Subquestion 1

The evidence for Subquestion 1 is summarised in Table 3.2.

Table 3.2 Summary of findings – Subquestion 1

In Rh D negative pregnant women with no preformed anti-D, is universal routine antenatal prophylaxis with one dose of Rh D immunoglobulin as effective at preventing Rh D alloimmunisation as universal routine prophylaxis with two doses of Rh D immunoglobulin?

<table>
<thead>
<tr>
<th>Patient or population: Rh D negative pregnant women with no preformed anti-D</th>
<th>Setting: Obstetrics and maternity, primary setting</th>
<th>Intervention: Universal antenatal Rh D immunoprophylaxis (single dose)</th>
<th>Comparison: Universal antenatal Rh D immunoprophylaxis (two doses)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>No of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence of Rh D alloimmunisation</td>
<td>Risk with RAADP (one dose)</td>
<td>Risk with RAADP (two doses)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No evidence found</td>
<td>–</td>
<td>–</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incidence of a positive test for FMH</td>
<td>Risk with RAADP (one dose)</td>
<td>Risk with RAADP (two doses)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No studies identified</td>
<td>–</td>
<td>–</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum anti-D levels at birth</td>
<td>Risk with RAADP (one dose)</td>
<td>Risk with RAADP (two doses)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complete data not available (abstract only).</td>
<td></td>
<td></td>
<td>(1 RCT)</td>
<td>VERY LOW **</td>
</tr>
<tr>
<td>The proportion of women with undetectable anti-D at delivery was 45.2% vs 14.2% (OR 5.0; 95% CI NR; p&lt;0.001), favouring the two-dose regimen</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse neonatal events</td>
<td>Risk with RAADP (one dose)</td>
<td>Risk with RAADP (two doses)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No studies identified</td>
<td>–</td>
<td>–</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse maternal events</td>
<td>Risk with RAADP (one dose)</td>
<td>Risk with RAADP (two doses)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No studies identified</td>
<td>–</td>
<td>–</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Incidence of Rh D alloimmunisation (one dose, any timepoint) | Risk with RAADP (one or two doses) | Risk with no RAADP | | |
|---|---|---|---|
| 4 per 1000 (1 to 9) | 12 per 1000 | RR 0.31 (0.12 to 0.80) | 36,555 (4 observational studies) | VERY LOW c,d,e,f,h,j,k |
| Incidence of Rh D alloimmunisation (two doses, any timepoint) | Risk with RAADP (one or two doses) | Risk with no RAADP | | |
| 3 per 1000 (2 to 5) | 10 per 1000 | RR 0.32 (0.20 to 0.51) | 15,264 (6 observational studies) | VERY LOW c,d,e,f,h,j,k |
| Incidence of Rh D alloimmunisation (one dose, estimated) | Risk with RAADP (one or two doses) | Risk with no RAADP | | |
| In a meta-regression model, Turner et al. (2012) estimated an OR of 0.42 (95% CI 0.17, 0.73) for a single dose based on the relative effectiveness observed in published studies adjusted for bias and expert opinion. Using only studies relevant to the UK health system Pilgrim et al. (2009) estimated the risk of sensitisation using a single dose to be 0.34% (0.28, 0.40). | | | |

Prophylactic use of Rh D immunoglobulin in pregnancy care 24
In Rh D negative pregnant women with no preformed anti-D, is universal routine antenatal prophylaxis with one dose of Rh D immunoglobulin as effective at preventing Rh D alloimmunisation as universal routine prophylaxis with two doses of Rh D immunoglobulin?

**Patient or population:** Rh D negative pregnant women with no preformed anti-D  
**Setting:** Obstetrics and maternity, primary setting  
**Intervention:** Universal antenatal Rh D immunoprophylaxis (single dose)  
**Comparison:** Universal antenatal Rh D immunoprophylaxis (two doses)

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>Nº of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence of Rh D alloimmunisation (two doses, estimated)</td>
<td>In a meta-regression model, Turner et al. (2012) estimated an OR of 0.31 (95% CI 0.09, 0.65) for two doses of RAADP based on the relative effectiveness observed in published studies adjusted for bias and expert opinion. Using only studies relevant to the UK health system, Pilgrim et al. (2003) estimated the risk of sensitisation using two doses to be 0.30% (95% CI 0.22, 0.38).</td>
<td></td>
<td>(10 observational studies)</td>
<td>@@ LOW</td>
</tr>
</tbody>
</table>

*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).*

CI: confidence interval; FMH: fetomaternal haemorrhage; GRADE: Grading of Recommendations Assessment, Development and Evaluation; NR: not reported; OR: odds ratio; RAADP: routine antenatal anti-D prophylaxis; RCT: randomised controlled trial; RR: risk ratio

**Explanations**

a. Study is reported in a conference abstract and it is difficult to judge internal bias. Not all outcomes reported.  
b. One study only. Heterogeneity not assessed.  
c. One or more randomised studies with plausible bias that raise some doubts about the results.  
d. Missing data and exclusion of women may overestimate the clinical effectiveness of RAADP.  
e. One or more comparative observational studies with some important problems that seriously weaken the confidence in the results.  
f. Studies include historical or geographic controls and it is not clear whether intervention and control groups are comparable at baseline.  
g. Significant heterogeneity with substantial variability in effect estimates (I² statistic > 50%). Reduces confidence in the results to inform decision making.  
h. Obstetric practice and the baseline characteristics of the population may not be reflective of current practice; however, this was considered to not seriously alter the confidence in the effect.  
i. Includes one RCT and one quasi-RCT.  
j. No heterogeneity (I² statistic = 0%). Does not reduce confidence in results to inform decision making.  
k. Low event rate or wide CIs that cross the line of no effect. Confidence in the results is weak.  
l. Authors elicited expert opinion to estimate association between the relative and observed effectiveness for different dosing regimens.

**One or two doses versus placebo or no routine antenatal Rh D immunoprophylaxis**

Four systematic reviews were included that evaluated the effectiveness of RAADP in Rh D negative women. The reviews identified two Level II studies and nine Level III studies meeting the search criteria. One additional Level III study was identified in this review.

The primary studies used to inform on the effectiveness of routine antenatal immunoprophylaxis each varied with regards to the total dose of Rh D immunoglobulin administered (ranging from 500 international units [IU] to 3000 IU) and the timing of outcome measurement; therefore, several analyses were conducted to assess the implications for effectiveness. Many of the included studies had problems with study design, with concerns in relation to the comparability of treatment groups and missing data, and thus may overestimate the degree of protection provided by RAADP.
One-dose versus two-dose routine antenatal Rh D immunoprophylaxis

Three systematic reviews\(^1\)\(^1\), \(^3\)\(^3\), \(^4\)\(^3\) were identified that searched for head-to-head comparisons of one-dose versus two-dose RAADP regimes. None of the reviews identified any published evidence. Turner et al. (2012)\(^4\) provided an assessment based on expert opinion. McBain et al. (2015)\(^1\)\(^7\) noted an ongoing randomised controlled trial (RCT) (trial ID: ACTRN12613000661774) that compared a one-dose versus two-dose regime of RAADP, with primary outcomes of detectable anti-D antibodies at delivery and woman compliance. The results of this study, presented at the 21st Annual Congress of the Perinatal Society of Australia and New Zealand,\(^5\)\(^7\) as well as peer-reviewed results published after the inclusion dates for the systematic review,\(^6\)\(^8\) were considered by the ERG.

Incidence of Rh D alloimmunisation

One or two doses, any timepoint

The meta-analyses of the two available RCTs\(^6\)\(^6\), \(^6\)\(^6\) demonstrated a nonsignificant effect favouring routine third trimester antenatal administration of Rh D immunoprophylaxis.\(^1\)\(^1\) The study by Lee and Rawlinson (1995)\(^6\) used a lower dose (250 IU at 28 and 34 weeks) than is currently used in the Australian context (625 IU at 28 and 34 weeks). The meta-analyses reported by Turner et al. (2012),\(^4\) Pilgrim et al. (2009)\(^3\) and Chilcott et al. (2003)\(^10\) each showed an effect favouring RAADP, regardless of dose or timing of outcome measurement when compared with no RAADP. Turner et al. (2012)\(^4\) estimated the odds of Rh D alloimmunisation (during pregnancy, at birth or in a subsequent pregnancy) to be 0.31 (95% CI 0.17, 0.56), after adjusting for internal biases related to study design (e.g. woman selection, performance, attrition and outcome measurement) and external biases related to Rh D immunoprophylaxis (as rated by four assessors).

A meta-analysis of the eight Level III studies and the two RCTs revealed a significant effect favouring RAADP (any dose, any timepoint) compared with no RAADP for the incidence of Rh D alloimmunisation (RR 0.33; 95% CI 0.20, 0.53; p < 0.00001), but significant heterogeneity between studies was noted (I² = 70%).

Both Turner et al. (2012)\(^4\) and Pilgrim et al. (2009)\(^3\) also assessed whether the different dosing regimens influenced the effectiveness of Rh D immunoglobulin, but found no evidence to suggest whether one or two doses was superior. Turner et al. (2012)\(^4\) used a multidisciplinary panel of experts to first analyse risk of bias in ten studies of RAADP using various dose sizes and either one or two doses, then conducted a bias-adjusted meta-regression analysis to assess their relative effectiveness compared to no RAADP. Pilgrim et al. (2009)\(^3\) calculated unadjusted odds ratios for the risk of alloimmunisation. Both studies suggested similar effectiveness of a single dose (1500 IU) and a two dose regimen (500 IU per dose), and that both regimens were superior to no RAADP, though methodological issues with the studies included in both analyses limit the certainty of the effect sizes.

In general agreement with these studies, pooled data from the studies identified for this review revealed a significant effect favouring RAADP (any timepoint) compared with no RAADP for the incidence of Rh D alloimmunisation regardless of whether the regimen used a single dose (RR 0.31; 95% CI 0.12, 0.80; p = 0.02) or a two-dose regimen (RR 0.32; 95% CI 0.20, 0.51; p < 0.00001). When pooled data were assessed based on the total administered dose, an effect favouring a higher dose was observed. However, caution should be taken when interpreting these results, given the heterogeneity and quality of the included studies and the variability of the interventions, controls and outcomes reported.
One or two doses, timing of outcome measurement

The included primary studies measured the incidence of Rh D alloimmunisation at varying timepoints including those detected in a subsequent pregnancy, during pregnancy, at birth or within 3 days of delivery, or at postnatal follow-up. When assessed in a subsequent pregnancy (up to the first 12 weeks of pregnancy), a significant effect favouring RAADP (RR 0.43; 95% CI 0.31, 0.59; \( p < 0.00001; \) \( \left( I^2 = 0\% \right) \)) was observed. In contrast, when Rh D alloimmunisation was detected during pregnancy, the effect was nonsignificant (RR 0.33; 95% CI 0.08, 1.37; \( p = 0.13; \) \( \left( I^2 = 78\% \right) \)). The risk reduction associated with RAADP decreased over time, in a large part because fewer women in the control group were sensitised in the later studies. Explanations for this decrease are conjectural, but may reflect changes in pregnancy care over time not directly related to Rh D management.

An effect favouring RAADP was also observed among the eight studies that assessed the incidence of Rh D alloimmunisation at birth or within three days of delivery (RR 0.19; 95% CI 0.08, 0.45; \( p = 0.0001; \) \( \left( I^2 = 57\% \right) \)), and in the seven studies that assessed the incidence of Rh D alloimmunisation at postnatal follow-up (RR 0.19; 95% CI 0.13, 0.29; \( p < 0.00001; \) \( \left( I^2 = 0\% \right) \)).

Incidence of a positive test for FMH

One RCT\(^45\) found that a positive Kleihauer result was reported less often in women who received RAADP both during pregnancy (4.2% vs 7.0%; RR 0.60; 95% CI 0.41, 0.88; \( p = 0.0094 \)) and at birth of an Rh D positive baby (12.2% vs 20.2%; RR 0.60; 95% CI 0.46, 0.79; \( p = 0.00023 \)) when compared with women who did not receive RAADP. No between-group difference was observed for the number of women with a Kleihauer result of greater than one fetal red cell in 10 000 maternal red cells (5.2% vs 5.4%; RR 0.95; 95% CI 0.89, 1.54; \( p = 0.85 \)).

Adverse neonatal events

One RCT\(^45\) and three observational studies\(^49, 54, 56\) provided limited data on adverse neonatal events relating to RAADP. Huchet et al. (1987)\(^45\) reported one case of neonatal jaundice among neonates born to Rh D negative women who had received RAADP, compared with four cases among neonates born to women who had not received RAADP (0.11% vs 0.42%; RR 0.26; 95% CI 0.03, 2.30; \( p = 0.22 \)).

Both Tovey et al. (1983)\(^44\) and Bowman and Pollock (1987)\(^49\) reported several cases of treatment related to HDFN (either in a first or subsequent pregnancy) among Rh D negative women who had not received RAADP, but data relating to this outcome among the women who received RAADP were not reported.

Using case-finding from comprehensive laboratory records of women with Rh D alloantibodies, Koelewijn et al. (2008)\(^56\) calculated the prevalence of severe HDFN in their second ongoing pregnancies among Rh D negative women whose first pregnancy was after 1999 (when routine RAADP (intervention) was offered compared with those whose first pregnancy was before 1999 (before the introduction of RAADP in 1998). The study reported an incidence of severe HDFN of 0.1% if the first pregnancy had occurred in the epoch when RAADP was routinely available compared with 0.23% among the historical controls, correlating to a nonsignificant risk reduction of 0.55% (RR 0.45; 95% CI 0.10, 1.08, \( p = NR \)). However, when they excluded cases in which the history of postnatal and antenatal immunoprophylaxis was unknown, an effect favouring RAADP was observed (RR 0.51, 95% CI 0.9, 0.92; \( p = NR \)). No HDFN perinatal mortality was reported in either group. Unsurprisingly, once Rh D alloimmunisation had occurred, the risk of developing HDFN was the same in the intervention and control groups (19% vs 25%; RR 0.76; 95% CI 0.41, 1.42, \( p = NR \)).
Adverse maternal events attributed to Rh D immunoglobulin administration

None of the identified studies reported any adverse maternal events that could be attributed to administration of Rh D immunoglobulin.

Additional outcomes

One RCT provided limited data relating to serum anti-D antibody levels in Rh D negative pregnant women. Pennell et al. (2017) observed that the number of women with no anti-D antibody present at birth was higher in those who received the one-dose regime compared with the two-dose regime (45.2% vs 14.2%; OR 5.0; 95% CI not reported; p < 0.001). The relationship between a lack of detectable circulating anti-D antibody following Rh D immunoprophylaxis and risk of alloimmunisation detected in a subsequent pregnancy is not known. However, meta-analyses of effectiveness of RAADP (total dose) suggests a dose-response, which could have been mediated through longer duration of detectable passive anti-D.

3.1.4 Clinical commentary

Certainty of evidence

Although the comparative evidence for routine third trimester antenatal Rh D immunoprophylaxis (one or two doses) is of low to very low certainty, large population studies on the incidence of Rh D alloimmunisation show a reduction in risk following the introduction of this intervention. There is evidence that the incidence of FMH of sufficient size to cause Rh D alloimmunisation is higher in the third trimester than earlier in pregnancy. Antenatal immunoprophylaxis reduces the incidence of a subsequent positive test for FMH (moderate certainty of evidence), suggesting a reduced risk of Rh D alloimmunisation through effective removal of fetal red cells by the passive anti-D antibodies.

There was no conclusive evidence to suggest that a single dose of Rh D immunoglobulin (1500 IU) given at 28 weeks of pregnancy is superior or inferior to a two-dose regimen (500 IU to 625 IU) given at 28 and 34 weeks of pregnancy in terms of efficacy or safety.

Benefits and harms

Reducing the incidence of Rh D alloimmunisation is important because it is the most critical intermediate step for reducing the incidence of HDFN (and the consequent risk of serious fetal or neonatal morbidity or death). This also protects the woman from the need for invasive treatments that are needed if HDFN causes significant anaemia in an Rh D positive fetus as well as potential clinical complications that affect her own health. The intervention has an excellent safety record, with most errors associated with Rh D immunoglobulin related to omission or late administration.

A two-dose regimen may offer compliance benefits in comparison to single-dose regimen. A potential secondary benefit is that an Rh D negative pregnant woman may, because of the need for a second dose at 34 weeks of pregnancy, have an increased incentive to attend antenatal appointments later in her pregnancy.

Preference and values

Recent literature and international guidelines support the indications for, and the dosing of, Rh D immunoprophylaxis. However, maintenance of supply of Rh D immunoglobulin is a global issue. Boosting donors to maintain the supply of Rh D immunoglobulin poses potential clinical risks that raise ethical concerns, it also places a considerable burden on those donors.
A single injection at 28 weeks of pregnancy would reduce the burden on women and their caregivers by removing the need for a second injection at 34 weeks of pregnancy. However, the transition from two Rh D immunoglobulin doses of 625 IU (totalling 1250 IU) to a single Rh D immunoglobulin dose of 1500 IU would require an additional 250 IU of Rh D immunoglobulin per Rh D negative pregnancy. The requirement for additional product would place an increased burden on the donor pool, particularly on the small number of donors with high levels of anti-D antibodies.

**Resources and other considerations**

Costs associated with caring for Rh D alloimmunised women and their babies can be avoided with prophylactic administration of antenatal Rh D immunoglobulin. Routine antenatal immunoprophylaxis with Rh D immunoglobulin in Rh D negative women with no preformed anti-D antibodies has been available in Australia since the staged introduction of the national prophylaxis program started in 2003. The resources and costs associated with this program are considered reasonable.\(^{22}\) The logistics of implementing a single dose of Rh D immunoglobulin 1500 IU would require the supplier to manufacture and license a new product suitable for Australia. Any increased dose of Rh D immunoglobulin could potentially place an increased burden on the donor pool.

### 3.2 Universal sensitising event immunoprophylaxis in the first 12 weeks of pregnancy

**Question 2 – (Intervention)**

In Rh D negative women with no preformed anti-D who have experienced one of the following first trimester sensitising events – abdominal trauma, molar pregnancy, ectopic pregnancy, spontaneous miscarriage, threatened miscarriage or medical termination of pregnancy (with or without a curette) – does universal first trimester sensitising event prophylaxis with Rh D immunoglobulin prevent Rh D alloimmunisation?

Rh D immunoglobulin may be given to Rh D negative pregnant women with no preformed anti-D antibodies who have experienced a sensitising event in the first 12 weeks of pregnancy – abdominal trauma, molar pregnancy, ectopic pregnancy, spontaneous miscarriage, threatened miscarriage or medical termination of pregnancy (with or without a curette) – to prevent Rh D alloimmunisation. The literature search for this question aimed to establish whether such administration of Rh D immunoglobulin should be recommended.
3.2.1 Recommendations and Expert Opinion Points

<table>
<thead>
<tr>
<th>Identifier</th>
<th>Guidance – recommendations and expert opinion points</th>
</tr>
</thead>
<tbody>
<tr>
<td>R3</td>
<td>After the following sensitising events in the first 12 weeks of singleton or multiple pregnancy: miscarriage, termination of pregnancy (medical after 10 weeks’ gestation or surgical), ectopic pregnancy, molar pregnancy and chorionic villus sampling, the ERG recommends that a dose of Rh D immunoglobulin 250 IU be given to all Rh D negative women with no preformed anti-D antibodies to prevent Rh D alloimmunisation. (Strong recommendation, very low certainty of evidence about the size of effect)</td>
</tr>
<tr>
<td>R4</td>
<td>In the setting of medical termination of pregnancy before 10 weeks of gestation there is insufficient evidence to suggest the routine use of Rh D immunoglobulin. (Discretionary (weak) recommendation, expert consensus)</td>
</tr>
<tr>
<td>R5</td>
<td>In Rh D negative women with an ongoing pregnancy who have uterine bleeding in the first 12 weeks of pregnancy there is insufficient evidence to support the routine use of Rh D immunoglobulin. However, where the bleeding is repeated, heavy or associated with abdominal pain or significant pelvic trauma, immunoprophylaxis may be administered to women with no preformed anti-D antibodies. (Qualified (weak) recommendation, expert consensus)</td>
</tr>
<tr>
<td>EOP4</td>
<td>At all times when Rh D immunoglobulin is being administered for a sensitising event, it should be given as soon as practical within 72 hours. If delayed beyond 72 hours, the dose should be given up to 10 days from the sensitising event, but may have lower efficacy.</td>
</tr>
<tr>
<td>EOP5</td>
<td>For repeated sensitising events in the first 12 weeks of pregnancy, there is no evidence to guide practice. Specialist obstetric consultation is advised regarding further administration of Rh D immunoprophylaxis. For new sensitising events a repeated dose of Rh D immunoglobulin may be indicated. For ongoing uterine bleeding alone, a repeat dose of Rh D immunoglobulin (250 IU if during the first 12 weeks and 625 IU if after) may be appropriate after an interval of 6 weeks.</td>
</tr>
</tbody>
</table>

EOP: expert opinion point; ERG: Expert Reference Group; IU: international units; R: recommendation

3.2.2 Background
The aim of Question 2 was to examine whether administration of sensitising event immunoprophylaxis in the first 12 weeks of pregnancy should be recommended in the presence of any of the following events: abdominal trauma, molar pregnancy, threatened miscarriage and medical termination of pregnancy.
### 3.2.3 Summary of evidence

The evidence for Question 2 is summarised in Table 3.3.

#### Table 3.3 Summary of findings – Question 2

In Rh D negative women with no preformed anti-D who have experienced one of the following first trimester sensitising events – abdominal trauma, molar pregnancy, ectopic pregnancy, spontaneous miscarriage, threatened miscarriage or medical termination of pregnancy (with or without a curette), does universal first trimester sensitising event prophylaxis with Rh D immunoglobulin prevent Rh D alloimmunisation?

**Patient or population:** Rh D negative women with no preformed anti-D with a first 12 weeks of pregnancy sensitising event

**Setting:** Obstetrics and maternity, primary setting

**Intervention:** Routine sensitising event immunoprophylaxis

**Comparison:** Placebo or no sensitising event immunoprophylaxis

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>No of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence of Rh D alloimmunisation (4–6 months after spontaneous miscarriage and/or therapeutic evacuation) assessed with: Enzyme-Coombs screening</td>
<td>0 per 1000 (0 to 0)</td>
<td>RR 0.34 (0.02 to 6.69)</td>
<td>57 (1 observational study)</td>
<td>VERY LOW</td>
<td>The evidence is very uncertain about the effect of sensitising event immunoprophylaxis on the incidence of Rh D alloimmunisation 4–6 months after spontaneous miscarriage or therapeutic evacuation in Rh D negative women.</td>
</tr>
<tr>
<td>Incidence of Rh D alloimmunisation (4–6 months after incomplete miscarriage or therapeutic abortion) assessed with: Indirect Coombs</td>
<td>19 per 1000 (1 to 372)</td>
<td>RR 0.34 (0.02 to 6.69)</td>
<td>57 (1 observational study)</td>
<td>VERY LOW</td>
<td>The evidence is very uncertain about the effect of sensitising event immunoprophylaxis on the incidence of Rh D alloimmunisation 4–6 months after incomplete miscarriage or therapeutic abortion in Rh D negative women.</td>
</tr>
<tr>
<td>Incidence of Rh D alloimmunisation (at subsequent pregnancy after spontaneous miscarriage and/or therapeutic evacuation) assessed with: Enzyme-Coombs screening</td>
<td>0 per 1000 (0 to 0)</td>
<td>RR 0.34 (0.02 to 6.69)</td>
<td>57 (1 observational study)</td>
<td>VERY LOW</td>
<td>The evidence is very uncertain about the effect of sensitising event immunoprophylaxis on the incidence of Rh D alloimmunisation in a subsequent pregnancy after spontaneous miscarriage or therapeutic evacuation in Rh D negative women.</td>
</tr>
</tbody>
</table>
In Rh D negative women with no preformed anti-D who have experienced one of the following first trimester sensitising events – abdominal trauma, molar pregnancy, ectopic pregnancy, spontaneous miscarriage, threatened miscarriage or medical termination of pregnancy (with or without a curette), does universal first trimester sensitising event prophylaxis with Rh D immunoglobulin prevent Rh D alloimmunisation?

**Patient or population:** Rh D negative women with no preformed anti-D with a first 12 weeks of pregnancy sensitising event

**Setting:** Obstetrics and maternity, primary setting

**Intervention:** Routine sensitising event immunoprophylaxis

**Comparison:** Placebo or no sensitising event immunoprophylaxis

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>No of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence of Rh D alloimmunisation (at subsequent pregnancy after induced abortion) assessed with: Papain-treated cells or Indirect Coombs</td>
<td>14 per 1000</td>
<td>10 per 1000 (1 to 113)</td>
<td>RR 0.76 (0.07 to 8.21)</td>
<td>241 (1 observational study) (Simonovits et al. (1974)[63])</td>
<td>The evidence is very uncertain about the effect of sensitising event immunoprophylaxis on the incidence of Rh D alloimmunisation in a subsequent pregnancy after induced abortion in Rh D negative women</td>
</tr>
</tbody>
</table>

| Incidence of Rh D alloimmunisation (after abdominal trauma, molar pregnancy, ectopic pregnancy) | No comparative evidence found (National Collaborating Centre for Women’s and Children Health (2014)[64]) | – | – | The effect of sensitising event immunoprophylaxis on the incidence of Rh D alloimmunisation after abdominal trauma, molar pregnancy, or ectopic pregnancy in Rh D negative women is unknown. |

| Incidence of a positive test for FMH | No comparative evidence found (Karanth et al. (2013)[65]) | – | – | The effect of sensitising event immunoprophylaxis on the incidence of a positive test for FMH after abdominal trauma, molar pregnancy, or ectopic pregnancy in Rh D negative women is unknown. |

| Adverse neonatal events (e.g. jaundice) | No comparative evidence found (Karanth et al. (2013)[65]) | – | – | The effect of sensitising event immunoprophylaxis on the incidence of adverse neonatal events after abdominal trauma, molar pregnancy, or ectopic pregnancy in Rh D negative women is unknown. |
In Rh D negative women with no preformed anti-D who have experienced one of the following first trimester sensitising events – abdominal trauma, molar pregnancy, ectopic pregnancy, spontaneous miscarriage, threatened miscarriage or medical termination of pregnancy (with or without a curette), does universal first trimester sensitising event prophylaxis with Rh D immunoglobulin prevent Rh D alloimmunisation?

**Patient or population:** Rh D negative women with no preformed anti-D with a first 12 weeks of pregnancy sensitising event

**Setting:** Obstetrics and maternity, primary setting

**Intervention:** Routine sensitising event immunoprophylaxis

**Comparison:** Placebo or no sensitising event immunoprophylaxis

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>No of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse maternal events attributed to Rh D immunoprophylaxis</td>
<td>No comparative evidence found (Karanth et al. (2013)²¹)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>The effect of sensitising event immunoprophylaxis on the incidence of adverse maternal events after abdominal trauma, molar pregnancy, or ectopic pregnancy in Rh D negative women is unknown.</td>
</tr>
</tbody>
</table>

*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).*

CR: confidence interval; FMH: fetomaternal haemorrhage; GRADE: Grading of Recommendations Assessment, Development and Evaluation; RCT: randomised controlled trial; RR: risk ratio

**GRADE Working Group grades of evidence**

**High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect

**Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

**Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

**Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

**Explanations**

a. One randomised study with plausible bias that raises serious doubts about the results.

b. Method of randomisation not reported and unclear whether treatment allocation concealed. Some concerns with reporting bias and missing data.

c. Single study. Heterogeneity not assessed.

d. The evidence is not directly applicable to the target population or the Australian health care context, and it is difficult to judge whether it could be sensibly applied. Obstetric practice and the baseline characteristics of the population may not be reflective of current practice.

e. The study was conducted in the United States among Rh D negative women with complete miscarriage (n=9) or incomplete miscarriage with curettage (n=48). An unknown proportion of women had miscarriage outside the first 12 weeks of pregnancy and the intervention was administered at a dose higher than recommended in Australia (1500 IU vs 625 IU).

f. Small study not sufficiently powered to detect a statistically significant difference.

g. Single study. Publication bias likely.

h. Comparative study with some important problems that seriously weakens the confidence in the results.

i. Method of treatment allocation or blinding not reported. Some concerns with reporting bias and missing data.

j. The study was conducted in the United States among Rh D negative women who had therapeutic abortion (n=33) or were treated for incomplete miscarriage (n=24). Thirteen (22.8%) women were treated outside the first 13 weeks of pregnancy and the dose of Rhogam was not stated.

k. Low event rate or wide CIs that cross the line of no effect. Confidence in the results is weak.

l. The evidence is probably applicable to the Australian population and health care context, with some caveats.

m. The study was conducted in Hungary among Rh D negative women in their second pregnancy, whose first pregnancy was terminated in the first 12 weeks of pregnancy by induced abortion (method of termination not clear). The intervention was administered at the same dose as recommended in Australia (250 IU).
Two systematic reviews\textsuperscript{64, 65} were identified that evaluated the effectiveness of prophylactic Rh D immunoglobulin in response to a sensitising event in the first 12 weeks of pregnancy. The reviews included one Level II study\textsuperscript{62} and two Level III studies meeting the PICO criteria.\textsuperscript{61, 63} All three studies were published before the previous 2003 Rh D immunoglobulin guideline.\textsuperscript{1} No studies evaluating the use of prophylactic Rh D immunoglobulin in women with first trimester ectopic pregnancy, threatened miscarriage or molar pregnancy were identified.

The 2012 guidelines from the UK’s National Institute of Health and Care Excellence (NICE)\textsuperscript{64} also identified five noncomparative, descriptive studies\textsuperscript{66-70} of the incidence of alloimmunisation in women who did not receive Rh D immunoprophylaxis following first trimester obstetric events. These studies did not meet the PICO criteria for this review.

**Incidence of Rh D alloimmunisation**

Three studies\textsuperscript{61-63} assessed whether immunoprophylaxis with Rh D immunoglobulin prevented Rh D alloimmunisation after a sensitising event in the first 12 weeks of pregnancy. All three studies reported data on women who had either a miscarriage or therapeutic abortion, but no evidence was presented for women with a threatened miscarriage, ectopic pregnancy or molar pregnancy, or after abdominal trauma.

There were large variations within the included studies, with different doses of Rh D immunoglobulin used (1500 IU, 250 IU or not reported), different methods used to measure potential Rh D alloimmunisation (Enzyme-Coombs or Indirect Coombs), and different criteria with regards to the included sensitising events (spontaneous miscarriage or therapeutic evacuation). All included studies were small and were unlikely to be sufficiently powered to detect meaningful differences between comparator groups.

**Incidence 4–6 months after sensitising event**

Two studies\textsuperscript{61, 62} reported no increased risk of Rh D alloimmunisation between 4 and 6 months after miscarriage (spontaneous or incomplete) or therapeutic abortion. The RCT by Visscher and Visscher (1972)\textsuperscript{62} found no cases of Rh D alloimmunisation (Enzyme-Coombs test; 0/19 in the intervention group compared with 0/29 in the placebo group). The cohort study by Gavin (1972)\textsuperscript{61} also reported no significant increase in Rh D alloimmunisation (Indirect Coombs test; 0/21 in the intervention group compared with 2/36 in the placebo group). This did not reach statistical significance (RR 0.34; 95% CI 0.02, 6.69, \(p = 0.48\)).

**Incidence in a subsequent pregnancy**

Two studies\textsuperscript{62, 63} reported the incidence of alloimmunisation in a subsequent pregnancy after miscarriage (spontaneous or incomplete) or therapeutic abortion.

The study by Visscher and Visscher (1972)\textsuperscript{62} reported no Rh D alloimmunisation in nine subsequent Rh D positive pregnancies (6/19 from the intervention group, and 3/29 from the placebo group). It was not reported whether any of the other participants had given birth to an Rh D positive neonate beyond the follow-up period.

Simonovits et al. (1974)\textsuperscript{63} recorded three Rh D alloimmunisations among 241 Rh D negative women after therapeutic abortion (1 in the intervention group). No significant difference between treatment groups was observed (1.0% vs 1.4%; RR 0.76; 95% CI 0.0, 8.21, \(p = 0.82\)).
Incidence of a positive Kleihauer test
No studies were identified.

Adverse neonatal events
No studies were identified.

Adverse maternal events
No studies were identified.

3.2.4 Clinical commentary

Certainty of evidence
Certain events can lead to maternal exposure to fetal antigens during pregnancy or when giving birth. In the first 12 weeks of pregnancy such events include abdominal trauma, molar pregnancy, ectopic pregnancy, spontaneous miscarriage, threatened miscarriage or medical termination of pregnancy (with or without a curette).

Although the Rh D antigen is expressed on fetal RBCs from about 6 weeks of pregnancy (which would make alloimmunisation possible in the second half of the first trimester) the volume of fetal RBCs is very small at this gestation, so a low dose of Rh D immunoglobulin is justified for immunoprophylaxis.

The evidence is very uncertain about the effect of sensitising event immunoprophylaxis compared with placebo or no sensitising event immunoprophylaxis on the incidence of Rh D alloimmunisation after spontaneous miscarriage, incomplete miscarriage, therapeutic evacuation or induced abortion in Rh D negative women. The small size of the studies meant that detecting any benefit was unlikely.

The effectiveness of sensitising event immunoprophylaxis compared with placebo or no sensitising event immunoprophylaxis on the incidence of Rh D alloimmunisation after abdominal trauma, molar pregnancy or ectopic pregnancy is not known. The available evidence does not justify changes to the 2003 guidelines. However, the ERG has clarified the wording around threatened miscarriage and has added guidance related to molar pregnancy. This guidance is consistent with international guidelines.

A recommendation was made because these events are known, or likely to cause FMH and any event that leads to maternal exposure to fetal red cells could cause alloimmunisation. The risks of Rh D immunoprophylaxis are very low and are likely to be outweighed by potential benefit. A study comparing the alloimmunisation rates in Canada and the Netherlands over 10 years suggests that the Netherlands’ policy of selectively administering Rh D immunoprophylaxis for miscarriage only after 10 +0 weeks and for termination only after 7 +0 weeks does not result in a higher rate of alloimmunisation than in Canada, where immunoprophylaxis is offered for these events at any gestation.

Benefits and harms
There is a clear health benefit in avoiding sensitisation if possible. Reducing the incidence of Rh D alloimmunisation is important because it is the most critical intermediate step for reducing the incidence of HDFN (and the consequent risk of serious fetal or neonatal morbidity or death). This also protects the woman from the need for invasive treatments that are needed if HDFN causes significant anaemia in an Rh D positive fetus as well as potential clinical complications that affect her own health. The intervention has an excellent safety record.
Taken as a whole, the risk of sensitisation for Rh D negative women if they do not receive Rh D immunoprophylaxis following a sensitising event in the first 12 weeks of pregnancy outweighs the risk of harm. The risk of sensitisation increases when there is a greater likelihood of maternal tissues being exposed to fetal blood; surgical intervention greatly increases the risk of this happening.

**Preference and values**

Recent literature and international guidelines support the indications for, and dosing of, Rh D sensitising event immunoprophylaxis.

**Resources and other considerations**

Costs associated with caring for Rh D alloimmunised women and their babies can be avoided with prophylactic administration of antenatal Rh D immunoglobulin. Recommendations about sensitising event immunoprophylaxis with Rh D immunoglobulin in Rh D negative women with no preformed anti-D antibodies remain unchanged since the staged introduction of the national immunoprophylaxis program started in 2003. The resources and costs associated with this program are considered reasonable.  

The possible need for an increased dose of Rh D immunoglobulin for a multiple pregnancy was investigated in 2004 – it was found that no increased dose was required.  

3.3 Targeted routine antenatal or sensitising event immunoprophylaxis

**Question 3 – (Screening intervention)**

In Rh D negative pregnant women with no preformed anti-D, does targeted routine antenatal or sensitising event prophylaxis to women with an Rh D positive fetus increase the incidence of Rh D alloimmunisation compared with universal routine antenatal or sensitising event prophylaxis?

**Subquestion 3 – (Diagnostic accuracy)**

In Rh D negative pregnant women with no preformed anti-D, what is the diagnostic accuracy of non-invasive prenatal screening to identify fetal Rh D status?

A range of terms are used to describe the test for determining the RHD genotype of a fetus, including non-invasive prenatal screening, non-invasive prenatal assessment, non-invasive prenatal testing (NIPT) and non-invasive fetal RHD genotype testing. The term NIPT for fetal RHD is used in the recommendations and expert opinion points. The terminology used in the discussion of evidence reflects the terminology in the literature.

There are questions over the efficacy of targeted routine antenatal or sensitising event immunoprophylaxis in Rh D negative pregnant women, and about the diagnostic accuracy of NIPT to identify fetal Rh D status. NIPT for fetal RHD is a molecular blood group genotyping assay used to predict the Rh D status of the fetus in pregnancies where the mother is Rh D negative and the fetus is at risk of being affected by HDFN because of anti-D antibodies. It uses a maternal peripheral whole blood

---

* Letter from Professor Richard Smallwood AO, Chief Medical Officer, Commonwealth of Australia, to the product user re Rh (D) immunoglobulin (anti-D) in obstetrics, 4 November 2002.
sample for the extraction of cell-free DNA (cfDNA), which is analysed for the presence of the RHD gene. The literature search for this question aimed to establish whether targeted routine antenatal or sensitising event immunoprophylaxis to Rh D negative pregnant women with no preformed anti-D antibodies with an Rh D positive fetus increases the incidence of Rh D alloimmunisation compared with universal routine antenatal or sensitising event immunoprophylaxis. It also considered the diagnostic accuracy of NIPT to identify fetal Rh D status in Rh D negative pregnant women with no preformed anti-D antibodies.

3.3.1 Recommendations and Expert Opinion Points

<table>
<thead>
<tr>
<th>Identifier</th>
<th>Guidance – recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>R6</td>
<td>The ERG recommends that antenatal Rh D immunoprophylaxis in Rh D negative pregnant women with no preformed anti-D antibodies be targeted to those predicted to be carrying an Rh D positive fetus, based on NIPT for fetal RHD. This applies to both routine and sensitising event immunoprophylaxis, if the result of fetal RHD genotyping is available. (Strong recommendation, low certainty of evidence about the size of effect)</td>
</tr>
<tr>
<td>R7</td>
<td>If fetal Rh D status is not available or is uncertain, the ERG recommends that antenatal Rh D immunoprophylaxis be offered to Rh D negative pregnant women with no preformed anti-D antibodies. (Strong recommendation, low certainty of evidence about the size of effect)</td>
</tr>
<tr>
<td>R8</td>
<td>The ERG currently recommends that postnatal Rh D immunoprophylaxis (Rh D immunoglobulin 625 IU) continue to be administered to all Rh D negative women with no preformed anti-D antibodies who have a baby who is predicted to be Rh D positive based on NIPT for fetal RHD, or cord blood or neonatal Rh D typing. The cord blood or neonatal testing should be performed regardless of the results of NIPT for fetal RHD, but need not delay administration of Rh D immunoprophylaxis when the fetus has been shown to be RHD positive by NIPT testing. If the baby is Rh D positive, administer Rh D immunoglobulin even if the NIPT predicted an Rh D negative baby. (Strong recommendation, high certainty of evidence)</td>
</tr>
<tr>
<td>R9</td>
<td>The ERG recommends the testing of maternal blood to determine fetal RHD genotype in all Rh D negative pregnant women to enable targeted antenatal Rh D immunoprophylaxis. (Strong recommendation, high certainty of evidence about the accuracy of the test)</td>
</tr>
<tr>
<td>R10</td>
<td>The ERG recommends that test sensitivity be at least 99% in order to minimise the number of Rh D positive fetuses being missed by the test. (Strong recommendation, high certainty of evidence about the accuracy of the test)</td>
</tr>
<tr>
<td>R11</td>
<td>The ERG recommends NIPT for fetal RHD from 11+0 weeks of pregnancy because of higher test accuracy than at earlier weeks. (Strong recommendation, high certainty of evidence about the accuracy of the test)</td>
</tr>
</tbody>
</table>

EOP: Expert Opinion Point; ERG: Expert Reference Group; IU: international units; NIPT: Non-invasive prenatal testing; R: recommendation

* Cell-free DNA is colloquially known as cell-free fetal DNA (cffDNA).
3.3.2 Background

Question 3 was intended to examine whether targeted administration can replace universal administration of Rh D immunoprophylaxis during pregnancy, thereby reducing the number of women who need to receive Rh D immunoglobulin. Because targeted Rh D immunoprophylaxis relies on the identification of an Rh D positive fetus in pregnant women, a subquestion was included that focused on the diagnostic accuracy of NIPTs for testing Rh D negative women with no preformed anti-D antibodies. This technique replaces the requirement for invasive direct sampling methods for fetal DNA, such as amniocentesis or chorionic villus sampling (CVS) sampling.72

3.3.3 Summary of evidence

Summary of evidence – Question 3

The evidence for Question 3 is summarised in Table 3.4.

Table 3.4 Summary of findings – Question 3

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Impact</th>
<th>No of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence of Rh D alloimmunisation</td>
<td>No studies directly assessed the effect of targeted routine antenatal or sensitising event immunoprophylaxis on the incidence of Rh D alloimmunisation.</td>
<td>–</td>
<td>No direct evidence</td>
</tr>
<tr>
<td></td>
<td>One study (Saramago et al. (201873)) conducted a simulation based on diagnostic accuracy of the test and expected management in women with positive and negative test results. The report estimated targeted RAADP increased the risk of Rh D alloimmunisation from 281 per 100 000 pregnancy women with universal RAADP to 284 (base case scenario) or 309 (worst case scenario) per 100 000 (Saramago et al. (2018)73).</td>
<td>–</td>
<td>No direct evidence</td>
</tr>
<tr>
<td>Utilisation of Rh D immunoglobulin</td>
<td>No comparative studies directly assessed the effect of targeted routine antenatal or sensitising event immunoprophylaxis on utilisation of anti-D.</td>
<td>–</td>
<td>No direct evidence</td>
</tr>
<tr>
<td></td>
<td>One study (Saramago et al. (201873)) conducted a simulation based on data from three noncomparative studies (Grande et al. (2013),74 Banch Clausen et al. (2014)75 and Soothill et al. (2015)76), and estimated utilisation of anti-D would decrease by approximately 33.1% to 36.9.</td>
<td>–</td>
<td>No direct evidence</td>
</tr>
<tr>
<td>Incidence of a positive test for FMH</td>
<td>No studies directly assessed effect of targeted routine antenatal or sensitising event immunoprophylaxis on the incidence of a positive test for FMH.</td>
<td>–</td>
<td>No direct evidence</td>
</tr>
</tbody>
</table>
In Rh D negative pregnant women with no preformed anti-D, does targeted routine antenatal or sensitising event prophylaxis to women with an Rh D positive fetus increase the incidence of Rh D alloimmunisation compared with universal routine antenatal or sensitising event prophylaxis?

**Patient or population:** Rh D negative pregnant women with no preformed anti-D

**Setting:** Obstetrics and maternity, primary care

**Intervention:** Targeted antenatal Rh D immunoprophylaxis (based on NIPT)

**Comparison:** Universal antenatal Rh D immunoprophylaxis

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Impact</th>
<th>№ of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse neonatal events</td>
<td>No studies were identified that reported any data on adverse neonatal events relating to NIPT or antenatal anti-D administration.</td>
<td>-</td>
<td>No direct evidence</td>
</tr>
<tr>
<td>Adverse maternal events attributed to Rh D immunoprophylaxis</td>
<td>No studies were identified that reported any data on adverse maternal events relating to NIPT or antenatal anti-D administration.</td>
<td>-</td>
<td>No direct evidence</td>
</tr>
</tbody>
</table>

*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; FMH: fetomaternal haemorrhage; GRADE: Grading of Recommendations Assessment, Development and Evaluation; NIPT: non-invasive prenatal test; RAADP: routine antenatal anti-D prophylaxis

GRADE Working Group grades of evidence

- **High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect
- **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
- **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
- **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
Summary of evidence – Subquestion 3
The evidence for Subquestion 3 is summarised in Table 3.5.

Table 3.5 Summary of findings – Subquestion 3

In Rh D negative pregnant women with no preformed anti-D, what is the diagnostic accuracy of non-invasive prenatal screening to identify fetal Rh D status?

**Patient or population:** Rh D negative pregnant women with no preformed anti-D (for routine or sensitising event immunoprophylaxis)

**Setting:** Obstetrics and maternity, primary setting

**New test:** NIPT for fetal Rh D status

**Reference test:** Postnatal cord blood testing (or other neonatal sample) for fetal Rh D status or other non-invasive prenatal test for fetal Rh D status

**Range of sensitivities:** 0.93 to 1.00 | **Range of specificities:** 0.92 to 1.00

<table>
<thead>
<tr>
<th>Test result</th>
<th>Number of results per 1000 patients tested (95% CI)</th>
<th>Number of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>True positives</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assumed lower estimate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prevalence 55%</td>
<td>510 to 550</td>
<td>76 349 (48)</td>
<td>★★★★★ HIGH a,b,c,d,e</td>
<td>Around 57.3% to 62.0% of Rh D negative women would receive Rh D immunoglobulin. f</td>
</tr>
<tr>
<td>Prevalence 62%</td>
<td>575 to 620</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prevalence 75% Maximum reported prevalence in identified studies</td>
<td>696 to 750</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>False negatives</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0 to 40</td>
<td>0 to 45</td>
<td>0 to 54</td>
<td>Around 0 to 4.5% of Rh D negative women with an Rh D positive fetus would not receive Rh D immunoglobulin. g</td>
</tr>
<tr>
<td><strong>True negatives</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>412 to 450</td>
<td>348 to 380</td>
<td>229 to 250</td>
<td>Around 34.8 to 38.0% of Rh D negative women would avoid unnecessary Rh D immunoglobulin. h</td>
</tr>
<tr>
<td><strong>False positives</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0 to 38</td>
<td>0 to 32</td>
<td>0 to 21</td>
<td>Around 0 to 3.2% of women would unnecessarily receive Rh D immunoglobulin. i</td>
</tr>
<tr>
<td><strong>Inconclusive</strong>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Where possible, inconclusive results were treated as test positive</td>
<td></td>
<td></td>
<td>Approximately 6.7% of results are estimated to be inconclusive (Saramago 2018).</td>
</tr>
</tbody>
</table>

CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; NIPT: non-invasive prenatal test

**Explanations**

a. Despite some gaps in reporting, most included studies were judged to be at low risk of bias. Concerns relating to women selection bias (e.g. exclusion of multiple pregnancies or exclusion of sensitised women) or conduct of the index test (e.g. number of exons amplified and controls used) were small, and are not considered to have substantially altered the test results. Cord blood serology was the reference standard in all studies and was usually conducted independent of the index test.

b. Almost all studies were consistent, and any inconsistencies could be explained. Samples taken before 12 weeks of pregnancy would reduce confidence in the specificity of the test. Some studies did not report inconclusive results, which would favour the index test; however, this was not considered to have substantially reduced the confidence in the overall quality of evidence.

c. The evidence was considered applicable to the Australian health care context with some caveats. Much of the evidence is from Northern European countries with a predominantly Caucasian majority. This was considered comparable to the Australian context in which the prevalence of Rh D negative phenotype among donors is around 15%. The prevalence of Rh D negative babies born to Rh D negative women...
is estimated to be 38%, but the prevalence of specific RHD genotypes is not known. The meta-analyses by Zhu\textsuperscript{77} and Geifman-Holtzman\textsuperscript{74} were not included, because changes and improvements have occurred in how the test is conducted. It is expected that the screening test would, at a minimum, include primers for two exons (4, 5, 7 or 10), involve real-time quantitative polymerase chain reaction (RT-qPCR) and be conducted in duplicate.

d. Diagnostic performance may by overestimated if only high-throughput studies are considered (as reported in Saramago\textsuperscript{73}); therefore, the inclusion of Mackie\textsuperscript{79} and smaller studies was considered appropriate for the Australian context. Care should be taken when interpreting test results in women with multiple pregnancies, because this subgroup was excluded from the meta-analysis by Mackie\textsuperscript{79} and other studies.

e. Many studies were included. Smaller Cs were observed in the large studies with central reference laboratories and those that used thresholds to maintain an acceptable level of sensitivity, and thus confidence in the evidence from those studies is high. In small, single-centre studies, a wider confidence interval would suggest a lower certainty of evidence.

f. The prevalence of Rh D positive babies born to Rh negative women in Australia is not known, but it was considered reasonable to assume a similar prevalence as estimated for the UK (62% estimated by Saramago 2018\textsuperscript{73}). This is based on the prevalence of Rh D negative status in the donor population in Australia (15%), which is comparable with the UK.

g. Assuming that routine postnatal Rh D immunoprophylaxis continues, the likelihood of a woman with a false-negative result experiencing a sensitising event is approximately 0.3%.\textsuperscript{80} Of these events, the likelihood that sensitisation causes mild HDFN is 90% and that it causes severe morbidity is 10%. Among those with severe morbidity, fetal death is estimated to occur in 5%.\textsuperscript{41}

h. These women would avoid two injections of Rh D immunoglobulin (current recommendation is two doses at 28 and 34 weeks of pregnancy). This assumes the sampling is derived from bloods already taken, and that they would also not receive postnatal Rh D immunoglobulin after cord serology.

i. This is much smaller than the current rate of 35–40%, which occurs with universal routine antenatal Rh D immunoglobulin. No adverse effects are anticipated to occur in these women.

**Targeted antenatal Rh D immunoprophylaxis versus universal antenatal Rh D immunoprophylaxis**

One systematic review\textsuperscript{73} was identified that searched for evidence regarding the comparative effectiveness of targeted antenatal Rh D immunoprophylaxis against universal routine immunoprophylaxis. The report did not identify any head-to-head studies of targeted versus routine antenatal immunoprophylaxis regimes that met the criteria for this review. Assuming that any relevant primary studies had been identified in Saramago et al. (2018),\textsuperscript{73} the systematic screen of Level II and Level III studies was limited to studies published 6 months before the literature search date of that review (2015 onwards). No additional Level II or Level III studies were identified.

Saramago et al. (2018)\textsuperscript{73} was a published health technology assessment report conducted for the National Health Service (NHS) in the UK. The study examined the diagnostic accuracy of high-throughput NIPT and the clinical impacts of implementation of targeted antenatal immunoprophylaxis, to underpin an economic assessment. Seven observational studies were identified in the review of clinical effectiveness. Two studies\textsuperscript{28, 75} assessed the incidence of Rh D alloimmunisation in women receiving NIPT compared with controls (i.e. women who did not receive RAADP). The remaining five studies were single-armed, noncomparative cohort studies for women receiving NIPT only.\textsuperscript{26, 74, 76, 82, 83}

**Clinical effectiveness**

None of the identified studies provided sufficient information to assess clinical effectiveness; therefore, Saramago et al. (2018)\textsuperscript{73} conducted a Monte Carlo simulation relevant to the UK health system, based on data presented in each of the studies. The model was populated using results from the diagnostic accuracy of high-throughput NIPT to identify fetal Rh D status and other relevant parameters required to provide a link between the diagnostic accuracy, the impact of subsequent treatment decision, and the ultimate effect on health outcomes and costs. The sensitivity of NIPT used in the model was 99.79% (95% CI 99.52, 99.01) and the specificity was 95.42% (95% CI 95.42, 92.84).
The following clinical scenarios were considered:

- no antenatal Rh D immunoglobulin; postpartum Rh D immunoglobulin based on cord blood serology only (control)
- antenatal Rh D immunoglobulin offered to all Rh D negative women; postpartum Rh D immunoglobulin based on cord blood serology (current practice)
- antenatal Rh D immunoglobulin offered based on NIPT; postpartum Rh D immunoglobulin based on cord blood test for all Rh D negative women
- both antenatal and postpartum Rh D immunoglobulin based on NIPT only; no cord blood testing.

No additional studies to those identified by Saramago et al. (2018) were identified in this review; therefore, the results of the model were considered.

The authors noted that the determination of the Rh D status of the fetus through NIPT may affect the administration of Rh D immunoglobulin in three situations: following potentially sensitising events, before routine third trimester administration and at birth. In addition, NIPT results may affect postpartum maternal screening for alloimmunisation, screening for FMH and cord blood testing. The test is not perfect; thus, some women with an Rh D negative fetus will still receive Rh D immunoglobulin (e.g. those with an Rh D negative fetus who screen as ‘inconclusive’, those who fail to undertake the screening test and those with a false-positive test result).

The model from Saramago et al. (2018) estimated that targeted RAADP increased the risk of Rh D alloimmunisation from 281 per 100 000 pregnant women with universal RAADP to 284 (base case scenario) or 309 (worst case scenario) per 100 000. That is, the use of NIPT to determine whether women would receive Rh D immunoglobulin would increase the number of Rh D sensitisations by between 3 and 15 in 100 000 pregnancies if postpartum cord blood testing were continued, or between 15 and 28 per 100 000 women if postpartum cord blood testing were withdrawn (and postnatal Rh D immunoglobulin was given or withheld on the basis of the NIPT result). The range in numbers is due to different assumptions as to whether women who do not receive NIPT would still be offered RAADP.

**Use of Rh D immunoglobulin**

Based on an assumed compliance of 99%, the simulation model estimated that the use of NIPT to determine RAADP would reduce the number of Rh D negative women receiving Rh D immunoglobulin to between 62.7% and 65.9%. This corresponds to an estimated reduction in the use of Rh D immunoglobulin of between 33.1% and 36.9%. These results were sensitive to compliance, with the range in numbers being due to different assumptions as to whether women who do not receive NIPT would still be offered RAADP.

In this model, the number of women who would avoid unnecessary Rh D immunoprophylaxis would be reduced from 38.9% to 4.5–5.7%, and the number of women who would fail to receive needed immunoprophylaxis would increase from an estimated 0.6% to 1.2–3.2%. The estimated one-third reduction in the use of Rh D immunoglobulin corresponds with the observed numbers reported by Soothill et al. (2015) (29%) and Banch Clausen et al. (2014) (37.1%), which were used to inform the simulation model. It also corresponds with the reduction reported by Macher et al. (2012), who observed a 38% reduction in the use of Rh D immunoglobulin in a single centre in Spain.

---

*Assumptions that feed into the model are provided in Saramago et al. (2018)."
Incidence of a positive test for FMH
No studies were identified.

Adverse neonatal events
No studies were identified.

Adverse maternal events attributed to Rh D immunoglobulin administration
No studies were identified.

Diagnostic accuracy of NIPT for fetal Rh D status
Four systematic reviews were identified that examined the diagnostic accuracy of NIPT to identify fetal Rh D status.\textsuperscript{73, 77, 79, 85} The reviews included over 90 studies meeting their search criteria.

Assuming that relevant primary studies had been identified in the included systematic reviews, the screening of the Level II and Level III citations was limited to those published after the literature search date of Saramago et al. (2018).\textsuperscript{73} Studies excluded by the included reviews were also scrutinised for inclusion. Studies that were excluded were those of small sample size (N<200), conference abstracts that did not provide sufficient data, and those in which the NIPT was not conducted in a context considered similar to Australia (see Appendix B, Volume 2 of the technical report\textsuperscript{77}).

Five additional Level II studies\textsuperscript{84, 86-89} and six additional Level III studies\textsuperscript{90-95} were identified and subsequently included in this review.

Saramago et al. (2018)\textsuperscript{73} only considered studies that used high-throughput NIPT, defined by the authors as any NIPT that was conducted using an automatic robotic platform (including automated DNA extraction and liquid handling) able to process large numbers of samples rapidly for large-scale screening purposes. Studies in which the test was used to determine fetal genotype in women who had already been sensitised were excluded. There were no restrictions on gestational age or exclusion of tests conducted in multiple pregnancies. The literature search was conducted from database inception to February 2016, with eight studies meeting these inclusion criteria.

Mackie et al. (2017)\textsuperscript{79} looked at cfDNA NIPT in singleton pregnancies for various conditions including Rh status. The meta-analysis was restricted to cohort studies that used outcome at birth for the reference standard, but it was noted that 12 of the included studies used CVS or amniocentesis results as the reference standard. Thirty studies (10 290 tests) were identified that had been conducted in various countries, including Australia. Key concerns related to women selection bias and index test bias, with only 13 of 30 studies reporting inconclusive test results. The diagnostic accuracy of different test platforms – real-time quantitative polymerase chain reaction (PCR), conventional PCR and mass spectrometry – was explored.

Zhu et al. (2014)\textsuperscript{77} identified 41 publications (11 129 tests) that assessed NIPT for fetal Rh D status using cfDNA in maternal whole blood only. No details regarding the included studies or assessment of bias were provided. It is unclear whether any effort was made to ensure that duplicate sample results were not included. The diagnostic accuracy of testing was assessed by gestational age at time of sampling.
Geifman-Holtzman et al. (2006)\textsuperscript{65} identified 37 publications performing 44 protocols and involving 3261 samples. The meta-analysis was restricted to studies that used outcome at birth for the reference standard. Descriptions of the risk of bias assessment for the included studies were not presented, but the authors noted that 16 included studies reported 100% diagnostic accuracy in their fetal \textit{RHD} genotyping, and many authors excluded samples because of the absence of detectable DNA or the inability to verify fetal or neonatal blood type, suggesting possible reporting biases. The diagnostic accuracy of testing was assessed by gestational age at time of sampling.

The additional RCTs identified were performed in a variety of countries including Canada, Finland, Italy, Spain and the United States, and used NIPT of cfDNA in maternal plasma targeting exons 5 and 7 of the \textit{RHD} gene,\textsuperscript{84, 86, 89} exons 5, 7 and 10,\textsuperscript{87} or exons 4, 5 and 7, as well as probes for the 37-base pair insertion in exon 4 (\textit{RHD} pseudogene).\textsuperscript{83} The additional Level III studies were conducted in Australia, Cyprus, Denmark, Ireland, Norway and Poland, and used NIPT of cfDNA in maternal plasma targeting exons 5 and 7 of the \textit{RHD} gene,\textsuperscript{92} exons 5 and 10,\textsuperscript{90, 91, 94, 95} or exons 5, 7 and 10.\textsuperscript{93}

The reference standard used in all studies was serological testing at birth, except for one study in which it was not stated.\textsuperscript{94} The studies enrolled Rh D negative pregnant women with gestational ages ranging between 5 and 39 weeks. Participants were predominantly Caucasian. None of the studies reported whether any procedural complications were attributed to either test.

Some included studies were at risk of selection bias. Women who were Rh D alloimmunised were explicitly excluded in two studies,\textsuperscript{86, 88} and one study only included women with suspected red cell alloimmunisation.\textsuperscript{92} Multiple gestation pregnancies may pose an issue for NIPT (e.g. if twin fetuses have discordant Rh D status); thus, exclusion of multiple pregnancies may also introduce selection bias. Multiple pregnancies were included in five studies,\textsuperscript{84, 86-88, 91} whereas their inclusion or exclusion was not stated in the other studies.

Manfroi et al. (2018)\textsuperscript{87} recruited women who had partners known to be Rh D positive, or partners of unknown Rh D phenotype (while excluding those who had partners known to be Rh D negative). The study by Papasavva et al. (2016)\textsuperscript{93} was conducted in a Cypriot population, where the prevalence of Rh D negative serology was estimated to be 7.2% (95% CI 5, 10). In addition, the study enrolled pregnant women with Rh D positive partners. For these reasons, in both studies a higher proportion of Rh D positive neonates would be expected than among all Australian neonates born to Rh D negative women.

Inconclusive results were reported in only seven studies.\textsuperscript{86-88, 90, 91, 93, 95} Exclusion of inconclusive results would introduce bias in favour of the index test.

The sex-determining region Y (\textit{SRY}) gene was used as an internal control for male fetal DNA in three studies, which may also have introduced bias.\textsuperscript{84, 92, 93} Other studies used internal controls to account for the total genomic DNA.\textsuperscript{91, 94, 95} In the nationwide screening programs, no internal control was used.\textsuperscript{96}

**NIPT for fetal Rh D status sensitivity and specificity**

Each of the included studies varied in their inclusion criteria (e.g. exclusion of multiple pregnancies), how inconclusive test results were handled (e.g. counted as test positive or investigated further), gestational age at sampling and the conduct of the test (e.g. number and location of exons used, type of platform and source of fetal DNA sample). Therefore, several analyses were conducted to assess the implications for diagnostic performance (see subgroup analyses, below).
Saramago et al. (2018) conducted a bivariate meta-analysis of eight studies that were considered most applicable to the UK health care system. Sensitivity was estimated to be 99.66 (95% CI 99.24, 99.85) and specificity was 96.14 (95% CI 94.18, 97.46). The $I^2$ statistic for heterogeneity was 75% for sensitivity and 99% for specificity. The authors noted that the high heterogeneities are, in part, a consequence of the high accuracy of the test and the large size of the studies (and consequently small within-study variance), rather than being indicative of any clinically meaningful differences between studies, because $I^2$ increases as the average within-study variance declines.

Saramago et al. (2018) also conducted sensitivity analyses to adjust for potential bias associated with two of the studies that did not report inconclusive results (resulting in a potential overestimate of diagnostic accuracy). In this analysis, sensitivity was 99.62 (95% CI 99.06, 99.85) and specificity was 95.63 (95% CI 93.22, 97.21).

The bivariate meta-analysis reported by Mackie et al. (2017) provided a sensitivity of 99.3 (95% CI 98.2, 99.7) and a specificity of 98.4 (95% CI 96.4, 99.3). Seventeen of the 30 studies included in the meta-analysis did not report inconclusive results, which may result in an overestimation of test accuracy. The authors noted that the most common reasons given for inconclusive results (in order of frequency) were: no reason given, RHD gene variant, insufficient number of markers present from prespecified cut-off, test failure or low fetal fraction (of free DNA detected in maternal blood). The most common reasons for false-positive results were: presumed low fetal fraction (not quantified by authors), no reason given, presumed RHD gene variant (not confirmed), confirmed RHD gene variant, test failure, possible contamination, DNA degradation, pipetting error or incorrect neonatal blood testing.

The meta-analysis by Zhu et al. (2014) (random effects) included 44 studies, many of which probably overlapped with those included by Mackie et al. (2017), but full details regarding the included studies were not provided. It is likely that inconclusive results were not included in the analysis. Here, sensitivity was estimated to be 99 (95% CI 99, 99) and specificity was 98 (95% CI 97, 98). The $I^2$ statistic for heterogeneity was 80.5% for sensitivity and 78% for specificity; this is probably due to small within-study variance rather than representing clinically meaningful differences between studies.

Geifman-Holtzman et al. (2006) conducted two meta-analyses involving up to 44 protocols, with the random effects model estimating a sensitivity of 95.4 (95% CI 90.6, 97.8) and a specificity of 98.6 (95% CI 96.4, 99.5), and the Bayesian model estimating a sensitivity of 96.7 (95% CI 92.5, 98.9) and a specificity of 98.9 (95% CI 96.7, 99.9). Details of the included studies were not provided, but it is likely that inconclusive results and substandard samples were not included in the analysis.

For the Australian context, it was assumed women with inconclusive results would be treated as test positive (without further testing); therefore, for the purposes of analysis in this review, all reported inconclusive results were treated as test positive.

Among the 13 protocols (10 studies) identified in this review, 12 showed a sensitivity of 100%, meaning that all women with an Rh D positive fetus would be correctly identified. Picchiassi et al. (2015) reported a sensitivity of 92.8 (95% CI 86.9, 96.2), which is notably lower than the other studies and is probably due to the small sample size and the early gestational age (10–15 weeks of pregnancy) at which sampling for fetal DNA occurred (see subgroup analyses below).
The widest 95% confidence interval for sensitivity (95% CI 93 to 100) was observed in a small study conducted in Cyprus that involved 73 women with Rh D positive partners. This means that, potentially, up to 7% of women with an Rh D positive fetus would be incorrectly identified. The single reverse transcriptase PCR (RT-PCR) protocol reported by Macher et al. (2012) also had a wide confidence interval (95% CI 95, 100), which was improved with the transition to multiplex RT-PCR (95% CI 99, 100).

For diagnostic specificity, the protocols ranged between 91.60 (95% CI 89, 94) and 100 (95% CI 81, 100), meaning that up to 8.4% (between 11% and 6%) of women with an Rh D negative fetus would be incorrectly identified. The heterogeneity in specificity is likely to be a consequence of differences in reporting and handling of inconclusive tests.

A bivariate meta-analysis of included studies revealed a sensitivity of 0.997 (95% CI 0.994, 0.999) and specificity of 0.983 (95% CI 0.974, 0.989) (random effects correlation 0.412).

Subgroup analyses of sensitivity and specificity

Method of detection

Mackie et al. (2017) performed a subgroup analysis to assess whether different technologies or techniques used to detect Rh D status include diagnostic performance. Here, better diagnostic performance was observed with RT-PCR (sensitivity of 99.7; specificity of 98.9) than with conventional PCR (sensitivity of 92.4; specificity of 95.4). Saramago et al. (2018) noted that, because each country used a different machine to perform NIPT, a subgroup analysis by type of NIPT method was not feasible because it would be confounded by study location.

Sample source

Geifman-Holtzman et al. (2006) demonstrated a significant improvement in diagnostic performance using free fetal DNA from maternal serum, plasma or blood (diagnostic accuracy between 91.8 and 96.5%) compared with using DNA or RNA from fetal cells within maternal blood (diagnostic accuracy between 67.7% and 76.3%).

Alloimmunised women

Geifman-Holtzman et al. (2006) also performed a subgroup analysis of the diagnostic performance of NIPT in Rh D negative pregnant women who were alloimmunised. The analysis showed diagnostic accuracy to be 91.8% in this group.

Gestational age

Saramago et al. (2018) performed a subgroup analysis to determine the significance of gestational age on false-negative rate (FNR), false-positive rate (FPR) and number of inconclusive results in the included studies. This analysis was undertaken because of concerns that diagnostic sensitivity and specificity is worse in samples collected before 11 weeks of pregnancy (due to the lower amount of cfDNA in maternal blood). The study authors plotted FNR against gestational age of the included studies, and found that FNRs were higher before 11 weeks of pregnancy but were consistent after 11 weeks of pregnancy. No obvious relationship between gestational age and FPR or number of inconclusive results was observed.
Ethnicity
Saramago et al. (2018) intended to assess whether ethnicity affected diagnostic performance of NIPT for fetal Rh D status, but found the relevant data were not reported in any publication. All studies were conducted in Europe; hence, numbers of participants of non-white ethnicity were likely to be few.

Supplementary data provided in the study reported by de Haas 2016 revealed 100% sensitivity regardless of ethnicity (95% CI ranged from 93 to 100 in Asian and Hindustani populations). However, women of Creole ethnicity had noticeably lower specificity (71; 95% CI 57, 83) than women of European ethnicity (98; 95% CI 98, 98).

3.3.4 Clinical commentary

Certainty of evidence
NIPT for fetal Rh D status is considered highly accurate, with no apparent adverse effects. The test is less accurate when maternal blood is sampled earlier than 11 weeks of pregnancy, and evidence of the performance of the test in multiple pregnancies is very uncertain. The advice of including multiple pregnancies is in concordance with guidelines for similar programs internationally.

High-throughput testing methodology will need to be validated for the Australian context, with accreditation and standardisation consistent with international standards. Laboratory standardisation would also assist with the collection of data to monitor and track any change in the incidence of sensitisation associated with the introduction of NIPT for fetal RHD.

Test thresholds would preferably be set to a minimum of 99% sensitivity, to lessen the number of women with a false-negative test result. These women would be at risk of sensitisation, because they would not be offered antenatal Rh D immunoprophylaxis. It is expected that women with inconclusive test results would either need a repeat test, or would be treated as test positive (in which case, they would receive antenatal Rh D immunoprophylaxis, both routine and for sensitising events if required).

NIPT may be unable to predict the fetal RHD type when the mother has a weak or variant D type. Further investigation of the maternal D type by a reference laboratory can provide some guidance for the management of antenatal Rh D immunoglobulin prophylaxis. However, in most cases the pregnant woman should receive antenatal Rh D immunoglobulin as though the maternal blood type is Rh D negative and the fetus assumed to be positive. The blood group of the newborn should be confirmed at birth and postpartum Rh D immunoglobulin administered to women who have delivered an Rh D positive baby.

Given that cfDNA in maternal blood increases throughout the pregnancy, NIPT for fetal RHD can be undertaken at any time after 11+0 weeks. However, to determine fetal Rh D status before a sensitising event such as an episode of haemorrhage or an amniocentesis in the second trimester, NIPT for fetal RHD should be undertaken as soon as possible after 11+0 weeks.

There was no comparative evidence examining the clinical effectiveness of targeted Rh D immunoprophylaxis.

Certain knowledge of RhD negativity in the biologic father of the fetus can obviate the need for antenatal prophylaxis, however, paternal testing is not routinely recommended.

---

*a This study population overlaps with the population reported by Thurik et al. (2015) (96) and De Haas et al. (2012) (83) that was included in Saramago et al. (2018) (73).
Benefits and harms

It is estimated that the use of NIPT for fetal RHD will result in about 33–38% of Rh D negative women avoiding unnecessary exposure to blood products and receiving fewer injections during pregnancy. This will be balanced by the very small increased risk of Rh D alloimmunisation among women with false-negative results, leading to a theoretical increase in the incidence of HDFN and associated complications. This is in line with international guidelines.\textsuperscript{6, 25-34} Also, the knowledge that an Rh D negative woman is carrying an Rh D positive fetus may improve uptake and adherence to the recommended Rh D immunoprophylaxis regimen.

Potential issues include those surrounding the collection of DNA, and that some pregnant women may be aware that their partner is Rh D negative and therefore decline testing. There is a need for counselling in relation to NIPT for fetal RHD to address these and other issues, such as the accuracy of the test and the benefits of confirming the Rh D status of the fetus. Counselling should include reassurance that the testing is only for the presence or absence of a single gene, and that no other genetic profile or information will be sought or obtained.

Preference and values

Many pregnant women would prefer to minimise their exposure to blood products where clinically reasonable to do so. NIPT for fetal RHD offers the opportunity to avoid the unnecessary administration of Rh D immunoglobulin in about one-third of Rh D negative pregnant women.

The ERG suggests a national program of targeted Rh D immunoprophylaxis, to achieve the calculated reductions in requirement for antenatal immunoprophylaxis, needs to maintain universal access; that is, all Rh D negative women must have equity of access to NIPT for fetal RHD. Policy relating to universal access to NIPT for fetal RHD is outside the scope of this guideline.

Resources and other considerations

Currently, the number of donors for the Rh D immunoglobulin program to maintain an adequate supply of Rh D immunoglobulin is limited. NIPT for fetal RHD offers the opportunity to reduce the need for Rh D immunoglobulin.

It is expected that all neonates born to Rh D negative women would continue to have postpartum blood typing of a sample of neonatal or cord blood, and the women would have postnatal Rh D immunoprophylaxis, as required.
3.4 Risk of failure of Rh D immunoprophylaxis due to high BMI

**Question 4 – (Prognostic)**

In Rh D negative pregnant or postpartum women with no preformed anti-D, does increasing BMI increase the risk of failure of anti-D administration?

There is some concern that in Rh D negative pregnant or postpartum women with no preformed anti-D antibodies, a high BMI may increase the risk of failure of Rh D immunoglobulin administration. The literature search for this question aimed to establish whether BMI has an impact on the effectiveness of Rh D immunoglobulin administration.

### 3.4.1 Recommendations and Expert Opinion Points

<table>
<thead>
<tr>
<th>Identifier</th>
<th>Guidance – recommendations and expert opinion points</th>
</tr>
</thead>
<tbody>
<tr>
<td>R12</td>
<td>The ERG does not currently support an increased dose of Rh D immunoglobulin or changes in laboratory testing on the basis of high BMI in Rh D negative pregnant women. <em>(Weak recommendation, very low certainty of evidence about the size of effect)</em></td>
</tr>
<tr>
<td>EOP6</td>
<td>Rh D immunoglobulin must be given by deep intramuscular injection. For women with a BMI of more than 30, particular consideration should be given to factors that may affect the adequacy of the injection (e.g. the site of administration and the length of the needle used).</td>
</tr>
</tbody>
</table>

BMI: body mass index; EOP: expert opinion point; ERG: Expert Reference Group; R: recommendation

### 3.4.2 Background

The aim of Question 4 was to investigate whether an increasing BMI, maternal weight or any other weight-related factors impact the effectiveness of Rh D immunoglobulin dosing.
3.4.3 Summary of evidence

Summary of evidence – Question 4

The evidence for Question 4 is summarised in Table 3.6.

Table 3.6 Summary of findings – Question 4

In Rh D negative pregnant or postpartum women with no preformed anti-D, does increasing BMI increase the risk of failure of anti-D administration?

| Patient or population: Rh D negative women with increased BMI and no preformed anti-D | Setting: Obstetrics and maternity | Intervention: Increased dose of RAADP | Comparison: Not applicable |

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>No of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence of Rh D alloimmunisation (any timepoint)</td>
<td>No significant association between body mass index, mean body weight, weight &gt;75 kg or weight &gt;100 kg on the incidence of Rh alloimmunisation reported in a small case–control study.</td>
<td>42 cases 146 controls (1 observational study) (Koelewijn et al. 2009)</td>
<td>VERY LOW</td>
<td>Increasing BMI does not appear to have any effect on the incidence of Rh D alloimmunisation in Rh D negative women, but the evidence is very uncertain.</td>
</tr>
</tbody>
</table>

Anti-D serum levels after administration of Rh D immunoglobulin (two doses, 28 and 34 weeks’ gestation)

One small study reported a correlation between peak anti-D serum levels and maternal body surface area and weight measured at 7 days after the first dose but found no significant difference relating to persistence measured at 12 weeks after the first dose.

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>No of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-D serum levels after administration of Rh D immunoglobulin (two doses, 28 and 34 weeks’ gestation)</td>
<td></td>
<td>45 (1 observational study) (Mackenzie et al. 2006)</td>
<td>VERY LOW</td>
<td>Increasing body surface area (BSA) appears to have little to no effect on persistence of anti-D serum levels after administration of Rh D immunoglobulin (two doses, 28 and 34 weeks’ gestation) but the evidence is very uncertain.</td>
</tr>
</tbody>
</table>

Anti-D serum levels after administration of Rh D immunoglobulin (single dose, 28 weeks’ gestation)

In a single arm of an RCT, women with body weight greater than 80 kg (n = 2) had lower peak serum levels than women who weighed less than 80 kg (n = 6), but anti D Immunoglobulin remained quantifiable in both women at last scheduled follow-up (week 9 and 11).

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>No of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-D serum levels after administration of Rh D immunoglobulin (single dose, 28 weeks’ gestation)</td>
<td></td>
<td>(1 RCT) (Bichler et al. 2003)</td>
<td>VERY LOW</td>
<td>Increased body weight appears to have little to no effect on persistence of anti-D serum levels after administration of Rh D immunoglobulin (single dose, 28 weeks’ gestation) but the evidence is very uncertain.</td>
</tr>
</tbody>
</table>

Anti-D serum levels after delivery of an Rh D positive baby

Based on the general linear model over time, the study authors found each kg/m² BMI higher than 27 kg/m² reduced the Rh D immunoglobulin serum concentration by the calculated value.

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>No of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-D serum levels after delivery of an Rh D positive baby</td>
<td></td>
<td>26 (1 observational study) (Woelfer et al. 2004)</td>
<td>VERY LOW</td>
<td>Increasing BMI may result in reduced anti-D serum concentration after delivery of an Rh D positive baby but the evidence is very uncertain. The link between lower anti-D levels and incidence of Rh D alloimmunisation is unknown.</td>
</tr>
</tbody>
</table>

Incidence of a positive test for FMH

No studies reported this outcome.

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>No of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidence of a positive test for FMH</td>
<td></td>
<td>–</td>
<td>–</td>
<td>not reported</td>
</tr>
</tbody>
</table>
In Rh D negative pregnant or postpartum women with no preformed anti-D, does increasing BMI increase the risk of failure of anti-D administration?

**Patient or population:** Rh D negative women with increased BMI and no preformed anti-D

**Setting:** Obstetrics and maternity

**Intervention:** Increased dose of RAADP

**Comparison:** Not applicable

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>No of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse neonatal events (e.g. jaundice)</td>
<td>Risk with increased dose of RAADP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>No studies reported this outcome.</td>
<td></td>
<td></td>
<td>not reported</td>
</tr>
<tr>
<td>Adverse maternal events</td>
<td>A total of seven adverse events reported among five women, none of which were considered related to study drug.</td>
<td>(1 RCT)</td>
<td>VERY LOW (GRADE)</td>
<td></td>
</tr>
</tbody>
</table>

*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

BMI: body mass index; CI: confidence interval; FMH: fetomaternal haemorrhage; GRADE: Grading of Recommendations Assessment, Development and Evaluation; RAADP: routine antenatal anti-D prophylaxis; RCT: randomised controlled trial

**GRADE Working Group grades of evidence**

**High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect

**Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

**Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

**Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

**Explanations**

a. One case–control study that appears to provide sound evidence for a nonrandomised study but cannot be considered comparable to a well-performed RCT. There was an over-representation of women from the primary versus obstetric setting (3:1) in the control group compared with cases, resulting in the use of weighted data in the analysis. This was not considered to seriously affect the overall direction of effect.


c. Evidence is directly generalisable to the target population and applicable to the Australian healthcare system with some caveats. The study was conducted in The Netherlands in Rh D negative women who received Rh D immunoglobulin 1000 IU at 30 weeks of pregnancy and within 48 hours of giving birth to an Rh D positive baby. This is different to the recommended dose in Australia of Rh D immunoglobulin 625 IU at 28 and 34 weeks of pregnancy, and within 72 hours of giving birth to an Rh D positive baby.

d. The study is not statistically powered to inform decision making. A very small number of women with a high BMI were included.

e. One study with some important problems that seriously weaken the confidence in the results.

f. Small cohort with some concerns with reporting bias and missing data.

g. Evidence is directly generalisable to the target population and applicable to the Australian healthcare system with some caveats. The study was conducted in the UK in Rh D negative pregnant women. Rh D immunoglobulin 500 IU was administered at 28 and 34 weeks of pregnancy, but the dose was lower than recommended in Australia at Rh D immunoglobulin 625 IU.

h. Small cohort with insufficient longer term data to provide meaningful information relating to BMI and incidence of Rh D alloimmunisation in a subsequent pregnancy.

i. The study is too problematic to provide any useful evidence on the outcome of interest.

j. Evidence is probably generalisable to the target population but difficult to judge whether it is sensible to apply it to the Australian health care system. The study was conducted in Germany in Rh D negative women. Rh D immunoglobulin (1500 IU) was administered at 28 weeks’ gestation, which is different to that recommended in Australia (Rh D immunoglobulin 625 IU at 28 and 34 weeks’ gestation). The correlation between body weight and BMI is poor, with the BMI of woman 12 being 26.79 and woman 9 being 32.29.

k. One observational study that appears to provide sound evidence for a nonrandomised study but cannot be considered comparable to a well-performed RCT.

l. Evidence is directly generalisable to the target population and is applicable to the Australian health care system with some caveats. The study was conducted in Austria in Rh D negative women who had delivered an Rh D positive baby. Rh D immunoglobulin was administered within 72 hours of birth, but at a dose higher than that recommended in Australia (1500 IU vs 625 IU).

m. Small study unlikely to be sufficiently powered to detect a statistically significant difference.
There were no Level I studies, two Level II studies\textsuperscript{99,101} and two Level III studies\textsuperscript{98,100} identified that provided some evidence relating maternal body weight to Rh D immunoglobulin administration.

MacKenzie et al. (2006)\textsuperscript{98} was a prospective cohort study set in the UK, which evaluated serum levels of Rh D immunoglobulin with respect to BMI and body surface area (BSA). The study was assessed to have an overall serious risk of bias due to insufficient reporting of outcome data, and the cohort was too small (N=45) to provide any useful information relating to the association between BMI and persistence of anti-D antibodies.

Woelfer et al. (2004)\textsuperscript{101} was a cohort study conducted in Austria that evaluated the effect of increasing BMI on Rh D immunoglobulin serum levels by constructing a multivariate linear regression model. The study was assessed to have a moderate risk of bias, but there was insufficient longer term data to provide useful information relating to an association between BMI and the incidence of Rh D alloimmunisation in a subsequent pregnancy.

Koelewijn et al. (2009)\textsuperscript{98} was a case–control study set in the Netherlands that examined risk factors associated with Rh D alloimmunisation in Rh D negative women during their first pregnancy. The cases were 42 women who developed antibodies detected upon first trimester screening in their second pregnancy, who were identified from a nationwide study in the years 1999, 2000, 2002, 2003 and 2004. Controls were selected over a 10-month period between September 2002 and June 2003 among women who had registered a negative red cell antibody screening results in the first 12 weeks of pregnancy (includes Rh D positive and Rh D negative parae-1). RAADP (1000 IU, single dose at week 30) had been available in the Netherlands since 1 July 1998. The study was assessed to have an overall moderate risk of bias, with a key concern being confounding and women selection bias. The study authors acknowledged an over-representation of women from the primary care setting (midwives and general practitioners) in the control group (as compared with the obstetric setting) compared with cases. To compensate, weighted data was used in the analysis.

Bichler et al. (2003)\textsuperscript{100} was a Phase II, open label, controlled trial conducted across seven gynaecological practices in Germany. The purpose of the study was to examine the pharmacokinetics of antenatal Rh D immunoglobulin when administered antenatally (intramuscular vs intravenous route). Serum Rh D immunoglobulin (1500 IU) was measured by flow cytometry, and the weight and height of each woman was provided. The study was assessed to have an overall critical risk of bias and was too problematic to provide any meaningful evidence.

**Incidence of Rh D alloimmunisation (any timepoint)**

One study\textsuperscript{98} was identified that considered whether increasing BMI increased the risk of failure of Rh D immunoglobulin administration (measured by the incidence of Rh D alloimmunisation in a second pregnancy). The study examined various risk factors for Rh D alloimmunisation in Dutch primiparous women, with the univariate analysis of risk factors suggesting no significant association between BMI, mean body weight or increased body weight (>75 kg and >100 kg), and the incidence of Rh D alloimmunisation.

The mean BMI in the Rh D alloimmunised group was estimated to be 23.8 ± 4.5 compared with a mean BMI of 24.0 ± 4.5 in the control group (mean difference [MD] = –0.20; 95% CI = –1.74, 1.34; \( p = 0.80 \)). There was also no difference in mean body weight, being 67.6 ± 11.5 kg among the Rh D alloimmunised women and 69.6 ± 13.3 kg in the control group (MD = –2.00; 95% CI = –6.09, 2.09; \( p = 0.34 \)). The authors also noted no association between Rh D alloimmunisation and maternal body weight greater than 75 kg, with 21.9% in the alloimmunised weighing more than 75 kg compared with 23.8% in the control group.
(\(p = 0.82\)). A similar observation was reported for women with maternal body weight greater than 100 kg (3.1% vs 3.3%, \(p = 0.71\)), although the number of cases may not have been sufficiently large to demonstrate an effect (there were fewer than two women in the alloimmunised group weighing > 100 kg).

This study may not have been sufficiently powered to detect a difference between populations due to the small number of cases (n = 42) and did not indicate when maternal body weight was measured. Also, the antenatal dose of Rh D immunoglobulin used in this study (1000 IU at 30 weeks) differs from the current Australian regimen (625 IU at 28 and 34 gestational weeks).

**Anti-D antibody levels (at any timepoint)**

Three studies\(^{99-102}\) identified a correlation between higher maternal body weight and lower peak serum anti-D antibody levels; however, sample sizes were small and the evidence was of very low quality. Further research is needed to determine whether lower levels of measurable anti-D antibodies in obese women correlates to higher rates of Rh D alloimmunisation.

Woelfer et al. (2004)\(^{102}\) assessed the influence of BMI on measurable anti-D antibody levels after delivery at one, two and three days, and at two weeks after administration. The study found that women with a BMI less than or equal to 27 kg/m\(^2\) had significantly higher concentrations of serum anti-D antibodies (ng/mL) than women with a BMI higher than 27 kg/m\(^2\). Using a general linear model, the study authors found each kg/m\(^2\) BMI higher than 27 kg/m\(^2\) reduced the serum concentration of anti-D antibodies by the calculated value (MD 4.2; 95% CI 6.4, 2.0; \(p < 0.002\) at day one up to MD 8.4; 95% CI 15.8, 1.1; \(p = 0.03\) at 2 weeks).

MacKenzie et al. (2006)\(^{99}\) reported a significant inverse relationship between peak serum concentration of anti-D antibodies (ng/mL) and low BSA (\(R^2 = 0.299; \ p = 0.002\)) or low maternal body weight (\(R^2 = 0.171; \ p = 0.006\)) when measured at seven days after the first dose (at 28 weeks of pregnancy). This did not significantly influence duration of persistence of anti-D antibodies at 12 weeks after the first dose when women with a maternal BSA of less than 1.80 m\(^2\), 1.8–1.99 m\(^2\) or greater than 2.00 m\(^2\) were compared (\(p\) not reported).

The study by Bichler et al. (2003)\(^{100}\) found that six women with a body weight less than 80 kg had a mean anti-D antibody level of 26.6 ng/mL, which was higher than the two women with a body weight greater than 80 kg (6.9 ng/mL and 10 ng/mL). Nevertheless, despite low peak serum levels of anti-D antibodies, the two women of higher body weight had quantifiable anti-D antibody levels up to the last scheduled blood sample (weeks 9 and 11, respectively).

**Incidence of a positive Keilhauer tests**

No studies were identified.

**Adverse neonatal events**

No studies were identified.

**Maternal adverse events**

No studies reported any maternal adverse events considered to be related to the study drug.
3.4.4 Clinical commentary

Certainty of evidence

Increasing BMI has not been shown to have any effect on the incidence of Rh D alloimmunisation in Rh D negative women. Several studies suggest that increasing BMI may affect peak serum levels of anti-D antibodies; however, there is no clear evidence that increasing BMI affects the persistence of anti-D antibodies. There is no established relationship between lower post-administration serum levels of anti-D antibodies and Rh D alloimmunisation or poor clinical outcomes.

Benefits and harms

All serious outcomes for Rh D alloimmunisation are uncommon in Australia. This is despite the fact that the proportion of women with a BMI of more than 30 is progressively increasing (such women now comprise almost one-third of all those giving birth in Australia).

Preference and values

It is preferable to maintain a consistent dose of Rh D immunoglobulin for all women, rather than having a dose specific to women with a BMI of more than 30. Also, it is clear that there is no evidence of the need for a separate dose for such women.

Resources and other considerations

There is insufficient evidence to support changes to the current recommendations.

3.5 Guidance based on the 2003 Guidelines on the prophylactic use of Rh D immunoglobulin (anti-D) in obstetrics

In addition to considering key areas of concern for a new evidence-based guideline, the ERG also considered the currency and relevance of guidance in the 2003 Rh D immunoglobulin guidelines.¹ The ERG agreed that the clinical guidance on sensitising event immunoprophylaxis beyond the first 12 weeks of pregnancy and postpartum immunoprophylaxis is still current, and therefore a review of the evidence is not required at this time. The existing guidance for both of these issues is presented below. The changes that have been made are based on consensus among the ERG.
### 3.5.1 Sensitising event immunoprophylaxis beyond the first 12 weeks of pregnancy in Rh D negative women – Expert Opinion Points

<table>
<thead>
<tr>
<th>Identifier</th>
<th>Guidance – expert opinion points</th>
</tr>
</thead>
</table>
| **EOP7**   | A dose of Rh D immunoglobulin 625 IU should be offered to every Rh D negative woman with no preformed anti-D antibodies, unless NIPT for fetal RHD has predicted the fetus to be Rh D negative, to ensure adequate protection against alloimmunisation for the following indications after 12\(^{th}\) weeks of pregnancy:  
  - genetic studies (chorionic villus sampling, amniocentesis and cordocentesis)  
  - abdominal trauma considered sufficient to cause FMH, even if FMH testing is negative  
  - each occasion of revealed or concealed antepartum haemorrhage. Where the woman suffers unexplained uterine pain the possibility of concealed antepartum haemorrhage (and the need for immunoprophylaxis) should be considered  
  - external cephalic version (successful or attempted)  
  - miscarriage or termination of pregnancy. |
| **EOP8**   | For sensitising events after 20 weeks of pregnancy, the magnitude of FMH should be assessed, and further doses of Rh D immunoglobulin administered if required.\(^a\)^\(^b\)^\(^c\)  
  - The first dose of the Rh D immunoglobulin should be given without waiting for the result of the test for FMH.  
  - Taken from Point 4.3 of the BCSH Guidelines for the estimation of fetomaternal haemorrhage.\(^7\)  
  - See Appendix C for guidance on dosing. |
| **EOP9**   | For ongoing uterine bleeding alone beyond 12 weeks’ gestation a further dose of Rh D immunoglobulin (625 IU) may be appropriate at 6 weekly intervals.\(^8\) New sensitising events should be managed with a further dose of Rh D immunoglobulin (625 IU) and assessment of FMH (after 20 weeks or where otherwise indicated) with additional dosing to cover large volume FMH if required (100 IU for each mL of fetal red cells beyond 6 mL).\(^a\)  
  - See Appendix C for guidance on dosing. |
| **EOP10**  | In reference to antenatal sensitising events after 20 weeks of pregnancy and after giving birth, a maternal sample to assess the volume of FMH should be taken before administration of Rh D immunoglobulin. However, at no time should Rh D immunoglobulin be delayed based on, or pending, the results of testing to quantitate FMH. Between 13 and 20 weeks of pregnancy, the magnitude of FMH may be assessed at clinical discretion. |
| **EOP11**  | The magnitude of the FMH should be assessed by a method capable of quantifying a haemorrhage of \(\geq\) 6 mL of fetal red cells (equivalent to 12 mL of whole blood). Flow cytometry is accepted as the most accurate quantitative test for FMH and is the method of choice for quantitation if readily available. Where FMH quantitation shows that FMH greater than that covered by the dose already administered has occurred, an additional dose or doses of Rh D immunoglobulin sufficient to provide immunoprophylaxis must be administered as soon as practical within 72 hours.\(^a\) If delayed beyond 72 hours, the dose should be given up to 10 days from the sensitising event, but may have lower efficacy.  
  - See Appendix C for guidance on dosing. |
<table>
<thead>
<tr>
<th>Identifier</th>
<th>Guidance – expert opinion points (cont.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EOP12</td>
<td>For large bleeds ≥6 mL of fetal red cells (equivalent to 12 mL of whole blood), follow-up testing should be performed on a sample collected 48 hours post intravenous Rh D immunoglobulin administration or 72 hours post intramuscular Rh D immunoglobulin administration, to determine whether further dosing is required. Supplemental Rh D immunoglobulin should be administered if the test for FMH is still positive.⁹ If testing for fetal cells is negative on a follow-up sample, no further testing is required. ⁹ See Appendix C for guidance on dosing.</td>
</tr>
</tbody>
</table>

BCSH: British Society for Haematology; EOP: expert opinion point; FMH: fetomaternal haemorrhage; IU: international units; NIPT: Non-invasive prenatal testing
4 Cost considerations

In 1999, the NHMRC published *Guidelines for the use of Rh D immunoglobulin in obstetrics*, with the aim of balancing best practice in the use of Rh D immunoglobulin with limited supply. The guidelines were based on a review of the literature and a cost-effectiveness analysis of six alternative strategies for the prevention of Rh D alloimmunisation in Australia.

Although the review process supported universal prophylaxis with Rh D immunoglobulin to Rh D negative women at 28 and 34 weeks of pregnancy, supply constraints meant that the NHMRC Working Party was unable to recommend universal prophylaxis at that time. This situation highlighted the need to consider options to increase the supply of Rh D immunoglobulin, to enable implementation of a universal antenatal prophylaxis program for all Rh D negative pregnant women.

In 2001, the Working Party was reconvened to review and update the guidelines, given developments in the availability of Rh D immunoglobulin since the publication of the 1999 guidelines. A literature search was commissioned to update the evidence base for the guidelines, and the cost–effectiveness data were reviewed.

A revised guideline was published in 2003 – it made various recommendations for the staged implementation of a full antenatal prophylaxis program, based on the results of the updated literature review and assessment of progress towards self-sufficiency in Rh D immunoglobulin. The intention of the 2003 guidelines was to progress towards full antenatal prophylaxis; thus, the updated cost analysis focused on the effect of the price of Rh D immunoglobulin and on the cost-effectiveness of its antenatal and postnatal use. The aim of the analysis was to investigate whether full antenatal prophylaxis remained cost-effective at different costs of Rh D immunoglobulin (imported and domestic supply), taking into account current evidence.

The results of the updated cost-effectiveness analysis suggested that both a postpartum program, and a postpartum plus antenatal prophylaxis program, remained well within the usual bounds of cost-effectiveness, given the prices per vial of Rh D immunoglobulin at that time. The Working Party concluded that antenatal prophylaxis appeared to be a cost-effective addition to a postpartum program, even at a relatively high price of Rh D immunoglobulin of A$115 per vial.

In developing the research questions for this guideline, the ERG did not explicitly include search strategies to identify evidence related to cost–effectiveness or resource implications of practice. However, where the literature searches conducted for the four clinical questions found information on cost-effectiveness or economic evaluations, this information was reviewed. Also analysed were cost-effectiveness studies for RAADP and NIPT that had been published since the release of the 2003 guidelines.

The following issues were identified when reviewing the studies:

- age of the studies
- only one of the studies was in the Australian context
- cost assumptions and inclusion of specific costs need to be validated for the Australian setting
- costs have an impact on a decentralised and centralised supply chain, including costs of testing and the donor programs
- differences in cost-effectiveness of a one-dose or two-dose RAADP regimen were a result of the differences in price of the products and administration costs.
The previous cost assessments completed for the Australian context were based on data from 1996; therefore, we recommend that a new independent assessment be conducted to assess the cost-effectiveness of the following strategies for the prevention of Rh D alloimmunisation. The assessment should cover:

- universal RAADP using one or two doses
- immunoprophylaxis using fetal Rh D status, determined by NIPT for fetal RHD or cord serology
- targeted antenatal Rh D immunoprophylaxis
  - with or without postnatal cord serology
  - centralised compared with decentralised testing
  - timing of testing
- universal sensitising or long-term event immunoprophylaxis in the first 12 weeks of pregnancy for threatened miscarriage compared with targeted immunoprophylaxis.

To inform the economic models, there is a need for additional evidence regarding uptake, women’s preferences, and errors and adverse events relating to administration of Rh D immunoglobulin, and episodes of Rh D sensitisation despite immunoprophylaxis. Also, it may be relevant to include the economic model disutility due to loss of fetus or long-term sequelae of HDFN (both of which were not included in the previous assessment), in which case, additional information on these outcomes may be required.

The availability of a more contemporary cost-effectiveness analysis is particularly important because of the limited supply of Rh D immunoglobulin available relative to the number of women and babies who may benefit from its use. A systematic approach to comparing costs and benefits in a variety of scenarios could help to inform decisions about the allocation of a scarce resource.
5 Supply considerations

5.1 Products currently available under the national blood arrangements

In Australia, Rh D immunoglobulin products are supplied and funded through arrangements managed by the NBA under the *National Blood Authority Act 2003* and National Blood Agreement.

There are two Rh D immunoglobulin products currently available in Australia. Details of these products are shown in Table 5.1.

Rh(D) Immunoglobulin-VF is a product for intramuscular administration manufactured from plasma collected in Australia. This product is supplied for the purposes of RAADP through the national prophylaxis program (see Chapter 1). Australia is self-sufficient in the supply of Rh(D) Immunoglobulin-VF.

In addition, the NBA manages the importation of an additional Rh D immunoglobulin product for exceptional purposes. The intravenous product currently imported under NBA arrangements is Rhophylac. This product is available only where intravenous administration is required, for use in large FMH where administration of intramuscular Rh D immunoglobulin is contraindicated or not practical, or in the case of inadvertent or emergency transfusion of Rh D positive blood to an Rh D negative woman of childbearing potential.

### Table 5.1. Products current for 2018–19 under the national blood arrangements

<table>
<thead>
<tr>
<th>Product</th>
<th>Presentation</th>
<th>Dose</th>
<th>Volume</th>
<th>Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rh(D) Immunoglobulin-VF</td>
<td>Single vial</td>
<td>250 IU</td>
<td>up to 2 mL</td>
<td>Slow deep intramuscular injection</td>
</tr>
<tr>
<td>Rh(D) Immunoglobulin-VF</td>
<td>Single vial</td>
<td>625 IU</td>
<td>up to 2 mL</td>
<td>Slow deep intramuscular injection</td>
</tr>
<tr>
<td>Rhophylac (imported)</td>
<td>Single use prefilled</td>
<td>1500 IU</td>
<td>2 mL</td>
<td>Intravenous or intramuscular injection Note: Available only where access to an intravenous preparation is required</td>
</tr>
</tbody>
</table>

Rh (D) Immunoglobulin-VF and Rhophylac are produced by CSL Behring and are distributed to approved health providers by the Australian Red Cross Lifeblood (Lifeblood). For detailed product information, see the CSL Behring website.¹

A current list of products available under the national blood arrangements is provided on the NBA website.² This list is updated when products change; the list also shows the price of the products for the current financial year.

5.2 Supply trends

The number of vials of Rh D immunoglobulin issued to health providers in Australia has remained steady since 2006–07, as highlighted in Figure 5.1, with a small decline in recent years.

---

¹ For information on Rh (D) Immunoglobulin-VF and Rhophylac see https://www.cslbehring.com.au/products/products-list
Product issued from the NBA can be provided to health providers in Australia, including public and private hospital pharmacies, public or private pathology laboratories, medical providers, and medical centres or clinics. The number of vials actually administered is not known because details of clinical use, inventory levels and wastage are not recorded nationally. Also, where products are used, it is unclear whether they have been used appropriately, in accordance with the clinical practice guidelines. Guidance on monitoring the use of Rh D immunoglobulin at an organisational level is provided in Chapter 8.

Figure 5.1. Vials of Rh D immunoglobulin issued since 2003–04
Note: Issues of Rhophylac are too small to appear on the graph.

The decline in products issued over recent years does not correlate with the change in births over the same period, as shown in Figure 5.2.

Figure 5.2. International units (IUs) of Rh D immunoglobulin issued since 2003–04
6 Safety of Rh D immunoglobulin

6.1 The effect of circulating prophylactically administered Rh D immunoglobulin in the fetal circulation

The literature search for the 2003 guidelines found one study that evaluated signs of haemolysis in babies of Rh D negative mothers who underwent prophylaxis with one or two doses of Rh D immunoglobulin during pregnancy. No statistically significant differences were found for any of the haematological variables between the babies of mothers who received one or two doses of Rh D immunoglobulin, or between the Rh D negative babies and the controls. Thus, the literature search of 2003 failed to find any new evidence for concern about fetal effects of prophylactic Rh D immunoglobulin (either one or two doses).

A search of the literature from 2001 to June 2019 found one study that matched babies born at 28–34 weeks of pregnancy after routine maternal Rh D immunoprophylaxis with controls. That study found higher bilirubin at birth and peak bilirubin in the first three days, but no differences in haematocrits at birth or day three, or in haematocrit nadir or number of transfusions. The low number of participants (N = 94) and the exclusion of babies for ABO incompatibility between mother and baby, which is an uncommon cause of a positive direct antiglobulin test (DAT), or significant haemolysis or jaundice in babies born in this gestation range, reduce the certainty of the authors’ conclusion that antenatal Rh D immunoprophylaxis does not cause clinically significant haemolysis in Rh D positive babies subsequently born preterm. A single case report of a 36-week gestation baby (born after maternal administration of 300 µg Rhogam at 28 weeks of pregnancy) identified marked jaundice (treated with phototherapy) and mild anaemia. Detailed laboratory studies supported a diagnosis of Rh D immunoglobulin-associated haemolysis in the newborn. Nevertheless, most cases of significant HDFN in babies whose mothers have received antenatal immunoprophylaxis appear to be attributable to maternal alloimmunisation before or despite antenatal Rh D immunoglobulin, rather than to the immunoprophylaxis itself.

There appear to have been no studies into the consequences of potential fetal exposure to high amounts of Rh D immunoglobulin after management of sensitising events.

Importantly, the investigation and management of Rh D positive, DAT-positive babies of Rh D negative mothers who have early or severe jaundice or anaemia should be similar, regardless of the suspected source of the antibody. Since clinically significant Rh D immunoglobulin-associated haemolysis in the newborn appears to be rare, the possibility of maternal alloimmunisation despite immunoprophylaxis should be investigated.

6.2 The risk of transmission of infectious organisms by administering Rh D immunoglobulin

Rh D immunoglobulin is derived from pooled donor plasma; therefore, it carries the potential of transmission of viral or other infectious organisms. To reduce the risk of such transmission, extra steps are taken when manufacturing Rh D immunoglobulin. For example, strict controls are applied to the selection of blood donors and donations, and the product is specially treated to remove and kill certain viruses; these special treatments are considered effective against both enveloped viruses (e.g. human immunodeficiency virus [HIV], hepatitis B virus and hepatitis C virus) and non-enveloped viruses (e.g. hepatitis A virus and human parvovirus B19).
Despite these measures, it is not possible to totally eliminate the risk of infectivity from viruses and other agents; however, the systematic review did not identify any studies reporting adverse maternal events attributed to Rh D immunoglobulin administration.

6.3 Other risks and benefits

A few case reports of maternal hypersensitivity reactions\textsuperscript{112} highlight the importance of administering Rh D immunoglobulin in locations where such reactions can be managed by appropriately trained providers.

Rh D immunoprophylaxis may have an added benefit of reducing risk of non-D alloimmunisation (e.g. alloimmunisation to other Rh antigens, or to Kell, Duffy or Kidd antigens).\textsuperscript{112}
7 Challenges

7.1 Donors

To ensure that the Australian demand for Rh D immunoglobulin can be met from domestic supply, Lifeblood collects high-titre anti-D plasma from a group of about 120 donors to produce Rh D immunoglobulin. The volume of plasma collected varies considerably month to month because of the small donor pool.

Challenges in maintaining this donor program include:

- the progressive retirement of Rh D donors, primarily on the grounds of age
- declining levels of anti-D antibody in Rh D donors, which occurs over time
- a reduction in the number of potential donors with anti-D antibodies due to a fall in the number of women immunised during pregnancy, resulting from the success of the prophylaxis program
- ethical considerations associated with increasing the anti-D antibody levels in blood donors by primary immunisation and boosting, as this requires a small transfusion of incompatible blood
- the significant effect on input if a donor withdraws from the program.

The shelf-life of plasma is 12 months. The shelf-life of Rh D immunoglobulin is two years once it has been manufactured from plasma.

The following strategies will be pursued to maintain the production of Rh D immunoglobulin in a practical, sustainable and ethical way:

- The program of immunisation of new Rh D immunoglobulin donors by Lifeblood will be maintained. This involves actively recruiting new donors for Rh D primary immunisation, and boosting to increase the pool of donors contributing to the supply of plasma for the production of Rh D immunoglobulin.
- CSL Behring and Lifeblood will continue to pursue ways of increasing anti-D plasma supply by increasing the yield of Rh D immunoglobulin from the anti-D plasma collected.
- The NBA will pursue the development of an educational program for health professionals on the efficient use of Rh D immunoglobulin.

7.2 Care pathways

In Australia, there is a wide range of pregnancy care pathways, as outlined in the National Maternity Services Plan.\textsuperscript{113} It is estimated that 92.7% of Australian women receive care through one of four models: private pregnancy care, combined pregnancy care, public hospital care and shared pregnancy care.

The trend of population and workforce movements to larger centres over the past decade has seen a decline in the number of facilities able to provide full pregnancy care for women in rural and remote areas. Providing continuity of care across the entire pregnancy care continuum requires a collaborative and flexible approach from maternity services and the maternity workforce, supported by integration of services, including:

- effective consultation and referral pathways
- effective clinical networks
- collaborative interdisciplinary professional relationships
- sound information sharing and communication channels.
The provision of community-based pregnancy care in remote locations is also an important strategy for providing care to women in remote parts of Australia. This collaborative approach to pregnancy care is particularly important for those women and babies whose care requires linkages to specialist services.

The wide range of pregnancy care pathways in Australia is seen in the different categories of health providers supplied with Rh D immunoglobulin, shown in Table 7.1. Details of who has prescribed and administered the products issued (e.g. midwives, nurses, obstetricians, medical officers or general practitioners) are not recorded at a state or national level.

Table 7.1 Vials issued by category and type of health providers in 2017–18

<table>
<thead>
<tr>
<th>Type</th>
<th>Category</th>
<th>Rh D Ig 250 IU</th>
<th>% of total 250 IU</th>
<th>Rh D Ig 625 IU</th>
<th>% of total 625 IU</th>
<th>Rhophylac 1500 IU</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Private</strong></td>
<td>Community pharmacy</td>
<td>8</td>
<td>0</td>
<td>–</td>
<td>0</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Hospital</td>
<td>1 769</td>
<td>9</td>
<td>2 782</td>
<td>3</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Hospital pharmacy</td>
<td>49</td>
<td>0</td>
<td>667</td>
<td>1</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Pathology laboratory</td>
<td>4 832</td>
<td>24</td>
<td>26 613</td>
<td>27</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>Medical providers</td>
<td>5 621</td>
<td>27</td>
<td>8 828</td>
<td>9</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Other</td>
<td>6</td>
<td>0</td>
<td>6</td>
<td>0</td>
<td>–</td>
</tr>
<tr>
<td><strong>Public</strong></td>
<td>Hospital</td>
<td>1 322</td>
<td>6</td>
<td>8 847</td>
<td>9</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>Hospital pharmacy</td>
<td>838</td>
<td>4</td>
<td>4 423</td>
<td>5</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Pathology laboratory</td>
<td>6 034</td>
<td>29</td>
<td>44 833</td>
<td>46</td>
<td>45</td>
</tr>
<tr>
<td></td>
<td>Other</td>
<td>11</td>
<td>0</td>
<td>37</td>
<td>0</td>
<td>–</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td>20 490</td>
<td>100</td>
<td>97 036</td>
<td>100</td>
<td>78</td>
</tr>
</tbody>
</table>

Ig: immunoglobulin; IU: international units

7.3 Measurement of product usage against clinical guidance

Gordon et al. (2017) estimated the number of women in 2017 requiring Rh D immunoglobulin for universal prophylaxis under the 2003 Guidelines on the prophylactic use of Rh D immunoglobulin (anti-D) in obstetrics. The numbers are shown in the first two columns of Table 7.2.

Using the recommendations on dosing for the events, it is estimated that 122 839 vials of Rh D immunoglobulin 625 IU could have been issued. However, the actual number of vials issued in 2017–18 was 97 036 (as per Table 7.1), suggesting an uptake of 79% against the 2003 Guidelines on the prophylactic use of Rh D immunoglobulin (anti-D) in obstetrics.

Table 7.2 Estimates of the number of women and number of vials required in 2017

<table>
<thead>
<tr>
<th>Event</th>
<th>Number of women</th>
<th>Dosing of 625 IU</th>
<th>Expected number of Rh D Ig 625 IU vials required</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antenatal</td>
<td>41 693</td>
<td>2 doses (28 and 34 weeks)</td>
<td>83 386</td>
</tr>
<tr>
<td>Postpartum</td>
<td>28 344</td>
<td>1 dose</td>
<td>28 344</td>
</tr>
<tr>
<td>Additional Rh D Ig for sensitising events and HDFN</td>
<td>11 109</td>
<td>1 dose</td>
<td>11 109</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>81 146</td>
<td></td>
<td><strong>122 839</strong></td>
</tr>
</tbody>
</table>

HDFN, haemolytic disease of the fetus and newborn; Ig, immunoglobulin; IU, international units

Based on Gordon et al. (2017), with the estimate for the number of women requiring treatment for antenatal events adjusted to 95% for the uptake.
7.4 Consent and the choice to decline Rh D immunoglobulin

Informed consent is a person’s voluntary decision about their health care that is made with knowledge and understanding of the benefits and risks involved.

The National Safety and Quality Health Service (NSQHS) Standards require health service organisations to partner with patients for their own care, and to ensure that patients and carers are informed about the risks and benefits of using blood and blood products, and all available treatment options. For private sector organisations where informed consent may be obtained in a process separate from the health service organisation, it is not intended that visiting medical officer practices are monitored. Rather, the health service organisation takes a risk management approach, and confirms with women on admission, or at the start of an episode of care, that they understand why they are there and what treatment they will receive.

As explained in the NSW Health Guideline: Maternity Rh (D) immunoglobulin (anti D) women should be advised that Rh D immunoglobulin is a blood product, and should be given a clear explanation of the potential risks and benefits of receiving Rh D immunoglobulin. Written information should also be provided; for example, You and your baby; important information for Rh (D) negative women.

Written consent may be obtained before administration of Rh D immunoglobulin immunoprophylaxis, by completing the appropriate records and documents. The discussion and the provision of written information should be documented in the medical record.

The ERG also recommends obtaining written or verbal informed consent for NIPT for fetal RHD. The information given to women should include:

- Who is tested?
- Why the testing is done?
- The only DNA test done will be for the gene that codes for the Rh D positive blood type in the fetus (modify if NIPT for RHD is done in combination with NIPT for aneuploidy or other reasons)

This has no link to forensic identification testing

Rh D negative mothers who decline NIPT for aneuploidy or other fetal diagnostic reasons should be offered NIPT for RHD, and the differences in the purpose of testing should be explained.
8 Monitoring the use of Rh D immunoglobulin

8.1 Documenting the use of Rh D immunoglobulin

As identified in the NSQHS Standards, accurately recording and reviewing a woman’s blood and blood product transfusion history, including any previous reactions and specific indications for use, in the woman’s health care record is essential to enable easy and accurate review of records.

Identifying any red cell antibodies, transfusion reactions or individual requirements specific to the woman will improve transfusion safety by reducing the risk of an adverse transfusion reaction. In addition, recording detailed information about transfusion is important, to allow for an audit of the woman’s health record for quality improvement processes and for traceability of all blood products (including Rh D immunoglobulin) from donors to recipients.

Documenting the indications for transfusion is essential to allow transfusions to be audited against guidelines as outlined in the NSQHS Standards.

8.2 Adverse event reporting and monitoring

Monitoring adverse events and analysing patterns of adverse events allows areas of risk to be identified and facilitates opportunities for improvement. Health professionals must report adverse events that occur as a result of administration of blood and blood products. Actions 7.7 and 7.8 of the NSQHS Blood Management Standard provides guidance on reporting adverse blood management events and strategies for improvement.

Health providers who administer Rh D immunoglobulin should have processes for reporting adverse events experienced by women to the hospital incident management system, pathology service provider, the product manufacturer, and the Therapeutic Goods Administration (TGA), in accordance with their requirements.

In Victoria, the Blood Matters Serious Transfusion Incident Reporting (STIR) system has started to report Rh D immunoglobulin administration incidents, and although the number of incidents was small in 2016-17, the types of incident reported through STIR mirror those identified by the 2017 Annual serious hazards of transfusion (SHOT) report. To understand current practice, Blood Matters conducted an audit to assess compliance with the Guidelines on the prophylactic use of Rh D immunoglobulin (anti-D) in obstetrics. It revealed a number of areas for improvement, including reporting adverse events related to Rh D immunoglobulin.

8.3 Audits

Audits of practice should be undertaken on a continuing basis, to monitor uptake of these guidelines. Where variance is identified in relation to uptake, these instances should be addressed through a quality improvement program.

Suggested audits for health service organisations are as follows:

- identify where products are infused or wasted
- identify cold chain breaches
- identify where there has been uptake or a lack of uptake of relevant guidelines
where a discrepancy between NIPT for fetal RHD and cord testing is noted, a report is sent to the laboratory that performed the NIPT for fetal RHD

- ensure that:
  - the woman’s records are clearly updated and reviewed
  - the woman’s consents are documented and placed in her medical record

- audit outcomes for women and their babies and haemovigilance activities.

Audits could be developed as an accreditation activity for the NSQHS Standards.114
9 Implementing, evaluating and maintaining the guideline

9.1 Communication and education
This guideline will be available within the public domains of the NBA and RANZCOG websites. The availability of the guideline will be communicated with all relevant clinical colleges and societies.

9.2 Review of these guidelines
This guideline will be reviewed every five years unless data or new clinical evidence relevant to clinical practice triggers the need for an earlier review. At that time, the NBA will convene a multidisciplinary group of clinical experts to undertake the review.

9.3 Feedback
To provide feedback and inform future reviews of this guideline, please send comments to:

    Email: guidelines@blood.gov.au
    Mail:    Guidelines
             National Blood Authority
             Locked Bag 8430
             Canberra ACT 2601

Any correspondence should be forwarded to the project manager for consideration in the next scheduled review.
References


32. National Institute of Health and Care Excellence (NICE) (2008). Routine antenatal anti-D prophylaxis for women who are rhesus D negative. NICE technology appraisal [TA156] [Internet]. (https://www.nice.org.uk/guidance/ta156)


Appendix A1  Abbreviations and acronyms

- **anti-D**: Rh D antibodies
- **BMI**: body mass index
- **BSA**: body surface area
- **cfDNA**: cell-free DNA
- **CI**: confidence interval
- **CVS**: chorionic villus sampling
- **DAT**: direct antiglobulin test
- **DNA**: deoxyribonucleic acid
- **EOP**: expert opinion point
- **ERG**: Expert Reference Group
- **FMH**: fetomaternal haemorrhage
- **FNR**: false-negative rate
- **FPR**: false-positive rate
- **GRADE**: Grading of Recommendations, Assessment, Development and Evaluation
- **HDFN**: haemolytic disease of the fetus and newborn
- **IAT**: indirect antiglobulin test
- **Ig**: immunoglobulin
- **IU**: international units
- **JBC**: Jurisdictional Blood Committee
- **NBA**: National Blood Authority
- **NHMRC**: National Health and Medical Research Council
- **NIPT**: non-invasive prenatal testing
- **NSQHS**: National Safety and Quality Health Service
- **NSW**: New South Wales
- **PCR**: Polymerase chain reaction
- **PICO**: population, intervention, comparator, outcome
- **R**: recommendation
- **RAADP**: routine antenatal anti-D prophylaxis
- **RANZCOG**: Royal Australian and New Zealand College of Obstetricians and Gynaecologists
- **RBC**: red blood cells
- **RCT**: randomised controlled trial
- **RNA**: ribonucleic acid
- **RT-PCR**: Real-time polymerase chain reaction
- **STIR**: Serious Transfusion Incident Reporting (Victorian Blood Matters program)
## Appendix A2  Terminology

<table>
<thead>
<tr>
<th>Terminology</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>250 IU, 625 IU, 1500 IU</td>
<td>Where the dose is presented in the guideline, it is given after the generic product name and in IU. Some other guidelines use micrograms (µg) as the unit of measurement – the conversion is as follows: 250 IU (50 µg), 625 IU (125 µg), 1500 IU (300 µg).</td>
</tr>
<tr>
<td>Antenatal, antepartum or prenatal</td>
<td>Each can be used depending on context. If referred to in the research questions, references or in content taken from published guidelines, the use as is stated in the original.</td>
</tr>
</tbody>
</table>
| Anti-D antibody                                                            | Consistent use of this term is used when referring to the circulating antibody wherever possible. Some variation in terminology may be present in the summary of evidence tables to reflect the terminology used in the corresponding literature.  
  Passive antibodies – Acquired from an external source such as administration of Rh D immunoglobulin.  
  Preformed antibodies – Acquired when an Rh D negative woman is exposed to Rh D positive blood and develops antibodies to Rh D (known as sensitisation). |
<p>| Baby or infant                                                             | The 2003 guideline(^1) refers to baby and infant; this guideline uses the term baby throughout.                                                                                                      |
| First trimester or first 12 weeks of pregnancy                            | If referred to in the research questions, references or in content from previous guidelines, the use is as stated in the original. In new recommendations, EOPs or commentaries, the term used is first 12 weeks of pregnancy, and refers to gestation up to 12(^{16}) weeks and days. |
| Immunisation or alloimmunisation                                           | Immunisation is used for donors and alloimmunisation for Rh D negative pregnant women.                                                                                                                                                                          |
| Immunoprophylaxis or prophylaxis                                           | If referred to in the research questions, references or content taken from published guidelines, the use as is stated in the original. In new recommendations, EOPs or commentaries, immunoprophylaxis is used.                                      |
| Large fetomaternal haemorrhage (FMH)                                      | (\geq 6) mL of fetal red cells (equivalent to 12 mL of whole blood)                                                                                                                                                                                           |
| Non-invasive prenatal testing (NIPT) for fetal RHD                        | A range of terms are used to describe the test for determining the RHD genotype of a fetus, including non-invasive prenatal screening, non-invasive prenatal assessment, non-invasive prenatal testing (NIPT) and non-invasive fetal RHD genotype testing. The term NIPT for fetal RHD is used in this guideline. |
| Postnatal or postpartum                                                    | If referred to in the research questions, references or in content taken from published guidelines, the use as is stated in the original. In new recommendations, EOPs or commentaries, the term used is postnatal. |</p>
<table>
<thead>
<tr>
<th><strong>Primigravida/e or first pregnancy/ies</strong></th>
<th>First pregnancy/ies is used in preference to primigravida/e; the latter is used only where it is referred to in a reference.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RHD</strong></td>
<td>RHD is used to refer to the genotype.</td>
</tr>
<tr>
<td><strong>Terminology</strong></td>
<td><strong>Notes</strong></td>
</tr>
<tr>
<td>Rh D immunoglobulin</td>
<td>The product <em>Rh D immunoglobulin</em> is discussed in generic terms (without brackets around the ‘D’). Brackets around the ‘D’ are used only when referring specifically to the CSL Behring product.</td>
</tr>
<tr>
<td>Rh D negative women or Rh D negative mothers</td>
<td>This is a woman who has Rh D negative blood type. The term <em>Rh D negative women</em> is used in preference to <em>Rh D negative mothers</em>.</td>
</tr>
<tr>
<td>Rh D positive or Rh D negative</td>
<td><em>Rh D positive</em> and <em>Rh D negative</em> are used in relation to blood type; the term <em>Rhesus</em> is used only where it is referred to in a reference.</td>
</tr>
<tr>
<td>Weeks’ gestation or weeks of pregnancy</td>
<td>If referred to in the research questions, references or content taken from published guidelines, the use as is stated in the original. In new recommendations, EOPs or commentaries, <em>weeks of pregnancy</em> is used.</td>
</tr>
</tbody>
</table>

EOP: expert opinion point; IU, international units;
Appendix B  Evidence gaps for potential research priorities

The review of evidence identified a number of areas where the evidence is uncertain or unknown. These areas, which are listed below, may present avenues for further research:

- What are the incidence and causes of Rh D alloimmunisation during pregnancy?
- What are the consequences (if any) of moving to a single-dose Rh D immunoglobulin regimen in terms of safety, efficacy, uptake and a woman’s acceptability?
- What is the correlation between low serum passive anti-D antibody levels in the late third trimester and incidence of Rh D alloimmunisation?
- What is the volume of fetal cells in the maternal circulation after the following sensitising events in the first 12 weeks of pregnancy: abdominal trauma, molar pregnancy, ectopic pregnancy, spontaneous miscarriage, threatened miscarriage or medical termination of pregnancy (with or without curettage)?
- What is the volume of fetal cells in the maternal circulation that increases the risk of Rh D alloimmunisation?
- What is the accuracy of non-invasive prenatal tests (NIPTs) for fetal RHD in Rh D negative women with multiple pregnancies?
- What is the acceptability of the non-invasive prenatal testing (NIPT) for fetal RHD among users?
- Are there alternatives to NIPT for fetal RHD for postnatal cord serology?
- Are neonatal exchange transfusion and intrauterine transfusion the most appropriate measures for assessing the number of fetuses with severe haemolytic disease of the fetus and newborn (HDFN), given clinical practice and thresholds for implementation have changed?
- What is the prevalence of RHD genotype as it relates to pregnant women or the current ethnic populations in Australia?
- What is the incidence of Rh D alloimmunisation as it relates to body mass index (BMI) in the Australian population (in particular, in women with a BMI of >30)?
- What are the outcomes of the more conservative approaches to sensitising event indications adopted by some other countries?
Appendix C  Dosing of Rh D immunoglobulin following fetomaternal haemorrhage quantitation

The purpose of this appendix is to guide the dosing of Rh D immunoglobulin following quantitation of fetomaternal haemorrhage (FMH) volume. Rh D immunoglobulin products that are currently available on the National Product list, and funded and supplied under the National Blood Agreement, are listed in Table 5.1 in Chapter 5.

For Rh D negative pregnant women, a maternal blood sample should be collected for quantitation of FMH following sensitising events after 20 weeks of pregnancy and after giving birth; the routine dose of Rh D immunoglobulin of 625 international units (IU) should be administered. This dose is sufficient to cover FMH of up to 6 mL Rh D positive fetal red cells (equivalent to about 12 mL of fetal whole blood), which will account for 99% of FMH.

For FMH volumes greater than 6 mL fetal red cells, an additional dose of Rh D immunoglobulin is required, and should be calculated at 100 IU per mL of fetal red cells in excess of 6 mL covered by the standard initial 625 IU dose. The required dose should be rounded up to the nearest full vial or vials.

Doses that require intramuscular injection of a volume of Rh D immunoglobulin of more than 5 mL volume should be divided and administered in separate intramuscular injections. Intravenous Rh D immunoglobulin may be used for the management of large FMH where administration of intramuscular Rh D immunoglobulin is either contraindicated or not practical.

For very large FMH volumes that would require more than two intramuscular injections, use of intravenous Rhophylac 1500 IU is recommended, at a dose of 100 IU/1 mL fetal red cells in excess of the 6 mL that is covered by the standard initial 625 IU dose.

After the initial 625 IU standard dose for sensitising events and following birth, the following table guides the additional Rh D immunoglobulin dosing for large FMH ≥6mL.

Table C.1 Dosing of Rh D immunoglobulin following fetomaternal haemorrhage quantitation

<table>
<thead>
<tr>
<th>FMH volume (fetal red cells)</th>
<th>Total dose of Rh D-Ig required</th>
<th>Initial dose of Rh D-Ig (625 IU) administered by IM injection for sensitising event or birth - covers FMH of up to 6 mL fetal red cells</th>
<th>Additional vials of Rh D-Ig (625 IU) to be administered by IM injection</th>
<th>Additional vials of Rhophylac (1500 IU) to be administered IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;6 mL</td>
<td>600 IU</td>
<td>1</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>≥6 - &lt;12 mL</td>
<td>1200 IU</td>
<td>1</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>≥12 - &lt;18 mL</td>
<td>1800 IU</td>
<td>1</td>
<td>2*</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1</td>
<td>1</td>
<td>1*</td>
</tr>
<tr>
<td>≥18 - &lt;21 mL</td>
<td>2100 IU</td>
<td>1</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>≥21 - &lt;36 mL</td>
<td>3600 IU</td>
<td>1</td>
<td>-</td>
<td>2</td>
</tr>
<tr>
<td>≥36 mL</td>
<td>FMH volume in mL fetal red cells multiplied by 100 IU</td>
<td>1</td>
<td>-</td>
<td>Total Rh D-Ig dose required (less 600 IU if already given initial dose) divided by 1500 IU and rounded up to nearest full number of vials</td>
</tr>
</tbody>
</table>

Specialist advice is recommended for any large FMH quantities and especially volumes ≥36 mL fetal red cells

FMH, fetomaternal haemorrhage; IM, intramuscular; IU, international units; IV, intravenous; Rh D-Ig, Rh D immunoglobulin

*2 vials of 625 IU can be administered as a single injection or as separate injections, however in either case to avoid discomfort associated with a larger volume IM injection or 2 additional injections, it may be more practical to offer IV Rhophylac 1500 IU instead.
Appendix D  Governance

D1 Governance framework

A multi-tiered governance framework was established by the NBA for the development of the guideline. The framework is depicted in Figure D1.

Figure D1: Governance arrangements

The Jurisdictional Blood Committee (JBC) is a committee of senior government officials with representation from the Australian Government, the six state governments and two territory governments. The JBC is responsible for all jurisdictional issues relating to the national blood supply, including planning, production, supply and budgeting. The JBC approved the process and expenditure to develop the guideline.

The NBA provided project management oversight and managed the procurement of all goods and services associated with the development of this guideline.

An evidence-based medicine expert was contracted by the NBA to assist the ERG with developing the scope of the research protocol to underpin the systematic review process.

A systematic review team and technical writer were contracted by the NBA to conduct systematic reviews of the scientific literature, and provide technical writing services to produce the guideline and associated technical report in collaboration with the ERG.

A multidisciplinary ERG was established by the NBA to provide expert knowledge and input, with members representing a range of clinical colleges, societies and organisations. The ERG:

- identified and developed the research questions and research parameters (i.e. PICO criteria and search terms) for the systematic review, with support from an evidence-based medicine expert
- provided advice on the type of evidence review required to support the update
- reviewed the list of abstracts compiled by the systematic review team and advised which articles should be retained in the evidence base for data extraction and analyses
- provided advice and clinical interpretation to guide the systematic review team
- reviewed the findings from the systematic review, with support from the systematic reviewer
- provided advice on current clinical practices in specific areas of expertise
- drafted the clinical guidance, with support from a medical writer
- reviewed public consultation feedback and revised the guideline accordingly
- proposed tools and strategies to support implementation.
D2 Membership

Expert Reference Group

<table>
<thead>
<tr>
<th>Name</th>
<th>Organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Marija Borosak</td>
<td>Royal College of Pathologists of Australasia</td>
</tr>
<tr>
<td>Dr James Daly</td>
<td>Australian and New Zealand Society of Blood Transfusion</td>
</tr>
<tr>
<td>Associate Professor Greg Duncombe</td>
<td>Royal Australian and New Zealand College of Obstetricians and Gynaecologists</td>
</tr>
<tr>
<td>Professor David Forbes</td>
<td>Jurisdictional Blood Committee</td>
</tr>
<tr>
<td>Professor Helen Liley</td>
<td>Royal Australasian College of Physicians</td>
</tr>
<tr>
<td>Dr Sharon Nowrojee</td>
<td>Jurisdictional Blood Committee</td>
</tr>
<tr>
<td>Professor Michael Peek</td>
<td>Royal Australian and New Zealand College of Obstetricians and Gynaecologists</td>
</tr>
<tr>
<td>Professor Michael Permezel</td>
<td>Royal Australian and New Zealand College of Obstetricians and Gynaecologists</td>
</tr>
<tr>
<td>Ms Kelley Stewart</td>
<td>Australian College of Midwives</td>
</tr>
<tr>
<td>Dr Amanda Thomson</td>
<td>Australian Red Cross Lifeblood</td>
</tr>
<tr>
<td>Dr Ken Wanguhu</td>
<td>Royal Australian College of General Practitioners</td>
</tr>
<tr>
<td>Ms Catherine Whitby</td>
<td>Consumer representative</td>
</tr>
</tbody>
</table>

Evidence-based medicine expert

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Sarah Norris</td>
<td>Project sponsor (research question development)</td>
</tr>
<tr>
<td></td>
<td>Health Research Consulting</td>
</tr>
<tr>
<td>Dr Kristina Harvey</td>
<td>Project lead (research question development)</td>
</tr>
<tr>
<td></td>
<td>Health Research Consulting</td>
</tr>
<tr>
<td>Dr Margaret Jorgensen</td>
<td>Project lead (research protocol, systematic review)</td>
</tr>
<tr>
<td></td>
<td>Health Technology Analysts</td>
</tr>
</tbody>
</table>

Systematic review team

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ms Stephanie Allerdice</td>
<td>Systematic reviewer</td>
</tr>
<tr>
<td></td>
<td>Health Technology Analysts</td>
</tr>
<tr>
<td>Mr Adrian Peacock</td>
<td>Systematic reviewer</td>
</tr>
<tr>
<td></td>
<td>Health Technology Analysts</td>
</tr>
<tr>
<td>Mr Kevin Phan</td>
<td>Systematic reviewer</td>
</tr>
<tr>
<td></td>
<td>Health Technology Analysts</td>
</tr>
</tbody>
</table>

Medical writing (guideline only) and technical editing

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Hilary Cadman</td>
<td>Medical writing (guideline only) and technical editing</td>
</tr>
<tr>
<td></td>
<td>Cadman Editing Services</td>
</tr>
</tbody>
</table>

Project management and committee secretariat

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ms Donna Cassoni</td>
<td>Project manager</td>
</tr>
<tr>
<td></td>
<td>National Blood Authority</td>
</tr>
<tr>
<td>Ms Sandra Cochrane</td>
<td>Project sponsor</td>
</tr>
<tr>
<td></td>
<td>National Blood Authority</td>
</tr>
<tr>
<td>Ms Emma Johnson</td>
<td>Project officer</td>
</tr>
<tr>
<td></td>
<td>National Blood Authority</td>
</tr>
</tbody>
</table>
Appendix E Process report

E1 Methodology

This guideline was developed by following the principles proposed by the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Working Group. It involved developing a set of research questions, systematically reviewing the scientific literature for evidence relating to those questions, and then developing and grading recommendations based on a structured assessment of the evidence. The methods used to apply this process are outlined in Chapter 2 and are given in full in the accompanying technical reports, which present in detail the methodology used to identify the evidence base (clinical questions addressed, documented systematic literature search, inclusion and exclusion criteria described), the characteristics and quality of the evidence base (data extraction and risk of bias forms), and detailed results presented by outcome (evidence summary tables and GRADE profiles).

The systematic review process was based on that described in the Cochrane handbook for systematic reviews of interventions. Covidence, a web-based platform for producing systematic reviews was used to store data that are compatible with the Cochrane data collection tools. RevMan was used for the main analyses and GRADEpro GDT software was used to record decisions and derive an overall GRADE (high, moderate, low, or very low) for the certainty of evidence for each outcome.

E2 Consensus process

In circumstances where no or insufficient evidence was identified, clinical guidance was developed by the Expert Reference Group (ERG) through a consensus-based process.

The consensus process was used where:

- the systematic review found insufficient evidence to address the clinical question
- the ERG determined that additional clinical practice guidance (expert opinion) was required for the evidence-based recommendations
- the development of clinical commentary was required.

The consensus process followed is presented below.

Stage 1 – Introduction

The consensus process, participants’ roles and responsibilities, ground rules and guiding principles are provided to members.

Stage 2 – Open discussion

The Chair opens the floor to a general discussion and suggestions for expert opinion or clinical commentary wording. The Chair provides an opportunity for concerns or issues to be raised.

Stage 3 – Resolve concerns

The Chair has the first option to resolve concerns by clarifying or changing the wording, or seeing whether those with concerns will stand aside. Where concerns are not resolved and the time is short, the discussion will be carried over to a later meeting.

---

1 Available at www.covidence.org
3 Available at www.gradepro.org
Stage 4 – First call for consensus
The Chair calls for consensus. If consensus is not reached, the ERG will consider the consensus process guiding principles and values, before the Chair calls for consensus again.

Stage 5 – Second call for consensus
If consensus is not reached:

- the member stands aside and the differing schools of thought are documented
- the member is not willing to withdraw the concern or stand aside, and the ERG declares itself blocked – the proposed clinical guidance is not accepted
- the member withdraws their concern and consensus is reached.

E3 Conflict of interest
All members of the ERG were asked to declare any interests before starting work on the guidelines. Members were advised that the National Blood Authority (NBA) regards a conflict of interest as referring to any situation where any professional, commercial, financial, personal or other interest or duty of the ERG member means that:

- the ERG member may not participate in the activity in a fair and impartial way; or
- the ERG member may have the opportunity to gain an improper benefit or advantage (for themselves or another person or organisation) as a result of participating in the activity.

ERG members were asked to take a broad and conservative view, and were provided with a conflict of interest form to draw out the domains and topics that could provide a source of a conflict of interest and subsequently affect proceedings within the ERG. Members were asked to declare both pecuniary and non-pecuniary interests:

- **Pecuniary interests** are possible financial advantages or disadvantages of participating in a process associated with businesses or companies that are providers of products, viewpoints or information that could be relevant to the ERG.

- **Non-pecuniary interests** can include the notions of reputation, pursuing a particular favoured practice or supporting a particular viewpoint of a group with whom members are affiliated.

New declarations were required to be declared to the NBA and Chair before the start of each meeting as a standing agenda item on each day of a meeting. The NBA kept a register of all declared interests. If an interest was declared, and the Chair decided that it should be considered by the ERG, the ERG decided by consensus whether it affected the proceedings. If the interest was considered to be competing or in conflict, the Chair directly managed the participation of that member in relation to discussions and decisions pertaining to the declared interest.

The Chair considered all declarations, and determined that none constituted a conflict of interest. The Chair’s declarations were reviewed by the NBA project management team and were not considered a conflict of interest. None of the NBA and evidence review contractors had any declarations.
E4 Public consultation

Public consultation was conducted for 7 weeks from 20 September 2019 to 8 November 2019, during which time the draft guideline was available on the NBA website. The NBA also sent formal notification to all organisations with a representative on the ERG, with a request that they disseminate the draft guideline within their networks.

Seventeen submissions were received. Some of those submissions included literature that had not been captured in the systematic review process due to it being published after the literature searches were conducted. The ERG met on 28 November 2019 to review the public consultation submissions and supporting documentation. Changes were made to the guideline to address comments and concerns raised in submissions, and to improve clarity. Where recommendations were revisited in light of new literature published, the ERG utilised an expert consensus process in reviewing and updating the clinical guidance.

E5 Appraisal of the guideline

The Appraisal of Guidelines for REsearch & Evaluation (AGREE) II instrument was developed to address the issue of variability in guideline quality and assesses the methodological rigour and transparency in which a guideline is developed. The post-public consultation version of the guideline was sent to two Australian reviewers, independent to the guideline development process, who used the AGREE II tool to assess the quality and usability of the guideline against international quality standards.

Both reviewers recommended the guideline for use, with one reviewer giving a rating of six out of seven and the other reviewer giving a rating of seven out of seven for overall quality of the guideline. Seven is the highest possible quality rating.